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Toward a Theory of Control of
Medical Experimentation With
Human Subjects: The Role
of Compensation
Bernard R. Adams*
Marilyn Shea-Stonumt
Although the use of human subjects in experimentation is not
new, a satisfactory mechanism for compensating victims of untoward
experiments has not yet been developed. The authors outline the
remedies that are now available or that could be developed under
common law principles. Rejecting these remedies as insufficient, the
authors suggest a system, patterned after workmen's compensation
laws, that can serve both as a control over researchers and as a just
and efficient means of compensating injured subjects of medical
experimentation.
I. INTRODUCTION
DISCOVERY IS the basis of progress in most areas of human en-deavor and discoveries are made usually only after long periods
of investigation. Behind every one of these discoveries lie costs that
must be borne by society and from each one come benefits that
must be distributed. In many cases, the balancing of costs against
benefits is a constant process. Investigation continues only after
the costs have been weighed against the benefits that have resulted
and the quantum of anticipated gain is found to be sufficient to
justify inquiry.
What is true for the progress of man is particularly evident in
the field of scientific research, including the medical sciences. In
this area the costs and benefits are clear, but they may be difficult
to quantify. In a laboratory experiment the scientist can estimate
the cost of his time, apparatus, and reactants, and the total of this
calculation can be compared to the gains that may result from the
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study. But in the final stages of any medical experiment there is
another factor that greatly complicates this calculus: the cost of hu-
man life. It must be decided whether the experiment should be
performed if it is potentially harmful to those who participate in it.
This article will examine the remedies available to compensate
those injured when this potential for harm is realized. It will first
define the unique problems presented by an effort to maximize both
deterrence and compensation in medical experimentation. The arti-
cle will then address the remedies designed to ensure compensation
of those injured in experimentation. The ability of each remedy
simultaneously to discourage harmful activity in advance and pro-
vide fair compensation to injured subjects after the fact will be con-
sidered. First, the existing common law remedial theories will be
examined. Secondly, the outlines of a comprehensive compensation
system will be proposed, and its capacity for handling these prob-
lems will be compared with that of the common law theories dis-
cussed. Finally, the possibility of instituting such a compensation
system in tandem with the existing common law remedies will be
considered.
II. DETERRENCE AND COMPENSATION
During the past decade, health professionals, government offi-
cials, philosophers, and legal scholars have come to realize that the
guidelines for the use of human beings as experimental subjects ex-
pressed in the Nuremburg and Helsinki Codes' have not been fully
implemented in the United States.2 Disregard of the principles of
1. United States v. Brandt, 2 Trials of War Criminals Before the Nurem-
berg Military Tribunals (The Medical Case) 181 (Military Tribunal I, 1947)
(Nuremberg Code); 271 NEwv ENG. J. MmD. 473 (1964) (Helsinki Code).
2. In 1972 exposure of the so-called Tuskegee Study focused public atten-
tion on the use and misuse of human subjects in experiments in the United
States. In this 30-year study by the United States Public Health Service, 400
poor black men diagnosed as having syphilis were examined periodically to
determine the nature of their disease and were reportedly induced through cash
payments and other promises to remain in the study and to entrust their treat-
ment to the physicians working on the project. During the course of the study,
penicillin was discovered to be an effective agent in the treatment of syphilis,
but such treatment was withheld from the study group. N.Y. Times, July 26,
1972, § 1, at 1, col. 1. An estimated 107 subjects died from the effects of
the disease. N.Y. Times, Sept. 12, 1972, § 1, at 23, col. 1.
Exposure of the Tuskegee Study occasioned reports cataloging other experi-
mental studies in which questions existed as to whether the subjects' rights had
been respected, including the following excerpt from the N.Y. Times, July 30,
1972, § 4, at 2, col. 4:
Even with a score of proclamations, codes, declarations, state-
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the Codes has led to a wide variety of practices in this country,
some of them shading into the unacceptable use of human subjects.3
Nevertheless, since society cannot expect medical science to prog-
ress at a desirable rate without reliance on human subjects, it has
not been seriously suggested that experimentation involving human
beings should cease altogether. 4 Rather, recent inquiry has concen-
ments and guidelines formulated since the Nuremberg Code that are
now supposed to be applied to all human experimentation, many
questionable studies have been done in recent years and, to loud cries
of "human guinea pigs," several have become embroiled in public
controversy. Almost without exception, they involve members of mi-
nority or disadvantaged groups.
Eight years ago, as part of a study of immunity to cancer, a lead-
ing New York cancer specialist injected live tumor cells into elderly
chronically ill patients without ever telling them in plain English
what they were being given and why. The researcher, Dr. Chester
Southam, was found guilty of "unprofessional conduct" by the state
Board of Regents. Fortunately, nothing went awry in the subjects,
all of whom rejected the tumor cells.
Nearly 400 poor women-most of them Mexican-Americans who
had already borne many children and had come to a San Antonio
family planning clinic for contraception-were enrolled in a study a
few years ago to determine whether oral contraceptives did in fact
cause psychological changes. All of the women were given identical-
looking drugs, most of them active contraceptive agents. But 76
women received a "dummy," or placebo drug. Seven pregnancies oc-
curred before the study was ended, six of them in the placebo group.
In 1967 coercion was charged in conjunction with a study in
which live hepatitis virus was injected into mentally retarded children
at Willowbrook State Hospital on Staten Island. Parents, who were
said to have a poor understanding of the study, were allegedly being
forced into consenting to their children's participation by way of get-
ting them into the crowded hospital.
The controversy dissipated after changes were made in the con-
sent procedure and the medical rationale was thoroughly explained.
But to this day, many scientists are still objecting to the use of men-
tally defective children in research, subjects who themselves cannot
possibly give informed consent to what is being done to them.
In the proceedings before the Board of Regents in the case involving the
injection of cancer cells into chronically ill patients, the researchers introduced
in their defense testimony of "well-known cancer and other professional re-
searchers" to the effect that the practices in question did not differ significantly
from those of the profession generally. Langer, Human Experimentation-
New York Verdict Affirms Patients' Rights, 151 ScIENcE 663, 666 (1966).
3. A review of the human experimentation conducted in 100 studies, se-
lected because of their consecutive publication in 1964 in a single "excellent"
medical journal, led a research scientist to conclude that 12 "seemed to be un-
ethical." Beecher, Ethics and Clinical Research, 274 NEw ENG. J. MED. 1354,
1355 (1966).
4. The recent promulgation of regulations governing the procedures to be
used in research involving human subjects at institutions receiving funds from
the Department of Health, Education, and Welfare is evidence of the consensus
that the use of human subjects is necessary. See 39 Fed. Reg. 18914-20
(1974).
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trated on defining appropriate circumstances for the use of human
subjects and deciding who those subjects should be. 5 Although
there is no general agreement on the circumstances that justify the
use of human subjects, it is now widely conceded that in any
event subjects must give their "free and informed consent." Think-
ers and commentators have turned, therefore, to the task of defining
this latter concept and determining if and how it can be achieved.6
Throughout this period of development, the stepchild question
has been how to compensate human volunteers who are injured in
the course of experimentation.7  The courts have made no attempt
to distinguish negligent injuries occurring in the purely therapeutic
setting from those arising in the experimental context.s  Some
writers, moreover, have indicated that a volunteer's free and in-
formed consent should operate as an assumption of the risk of non-
negligent injuries resulting from experimentation.9 Three factors
5. EXPERIMENTATION WITH HuMAN BEINGS (J. Katz ed. 1972); Ethical
Aspects of Experimentation with Human Subjects, 98 DAEALUS (1969) (entire
issue devoted to this subject).
6. See, e.g., H. BEECHER, RESEARCH ANm TE bwrvwuAL 18-32 (1970);
Blumgart, The Medical Framework for Viewing the Problem of Human Exper-
imentation, 98 DAEDALus 248, 255-62 (1969); Freund, Legal Frameworks for
Human Experimentation, 98 DAEALus 314, 322-24 (1969); Jonas, Philosophi-
cal Reflections on Experimenting with Human Subjects, 98 DAEDALUS 219, 220-
22 (1969); Macklin & Sherwin, Experimenting on Human Subjects: Philo-
sophical Perspectives, 25 CAsE W. Rrs. L. REv. 434 (1975).
7. Only three articles have addressed the issue directly: Calabresi, Reflec-
tions on Medical Experimentation in Humans, 98 DAEDALUs 387 (1969); Note,
Medical Experiment Insurance, 70 COLUM. L. REv. 965 (1970); Silverstein,
Compensating Those Injured Through Experimentation, 33 FED. B.J. 322
(1974). The first two articles present the poles of thought current in general
discussion of no-fault compensation. Calabresi views liability based on fault as
the foundation of due care in an individual's actions, whereas the latter Note
is strictly concerned with compensation of the victims. "The question is an
instance of a pervasive confrontation between two social philosophies-the one
putting primacy on responsibility, blameworthiness, rewards, and penalties for
behavior, the other stressing security of the victims against the impersonal
dooms of modem life." Freund, supra note 6, at 322. Silverstein does rec-
ognize the competing goals of deterrence and compensation in the federal sys-
tem of compensation outlined in his article. His proposal, however, does not
provide for the continued deterrent force of the growth of the common law
through private litigation.
8. Cf. Cooley v. Karp, 349 F. Supp. 827 (S.D. Tex. 1972), discussed in
note 30 infra and accompanying text.
9. 'The legal requisites for legitimate, liability-free experimentation can
be described in threefold form: ... informed, voluntary consent .... "
Freund, supra note 6, at 321 (emphasis added). Freund does proceed, how-
ever, to discuss briefly the possibility of "compensatory liability without fault"
Id. at 321-22.
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may have contributed to such a belief: First, the momentum of the
rhetoric used in the discussion of some of the other issues concern-
ing human experimentation; secondly, confusion with the principles
governing the effect of consent in a normal physician-patient rela-
tionship; and finally, the fiction that monetary compensation can
make an individual whole.
In the commentary on whether consenting human subjects should
be used in medical experimentation, support for the proposition that
they should has been drawn from comparisons to other situations in
which society has allowed volunteers to be exposed to grave risks be-
cause of the public need. Extension of these analogies in order to
decide how to allocate the human costs of medical experimentation,
however, leads to erroneous conclusions. Astronauts and soldiers
volunteering for dangerous assignments, for example, have been
cited as parallels to the subjects used in medical research, and these
modern heroes are in turn likened to the sacrificed victims of older
cultures.' 0 This latter comparison demonstrates the swiftness with
which rhetoric can lead to unwarranted conclusions. By reasoning
that human volunteers are like sacrificial victims of old, we are pro-
pelled toward attaching all of the characteristics of such victims to
these individuals. Specifically, we require them to bear the entire
cost of these pursuits. Admittedly, society might decide that the
human volunteer is the most appropriate bearer of the costs of un-
toward but nonnegligent results of medical experimentation. A de-
cision incorporating such a major value judgment, however, should
not be based on superficial analogies to related but readily distin-
guishable situations. The same care that has attended the consider-
ation of whether the use of human subjects should ever be permitted
should be taken in deciding how the costs of human experimenta-
tion should be distributed when either negligent or unavoidable in-
jury results.
Informed consent has been perhaps the most fluid concept of
the past decade in the field of medical malpractice." To a large
extent, this development reflects the rapidly changing and increas-
ingly complex procedures that are commonplace in modern medi-
cal treatment. Free and informed consent in the experimental con-
text, however, though it bears some resemblance to informed con-
sent in the normal therapeutic situation, has its own meaning and
10. Id. Cf. Burger, Reflections on Law and Experimental Medicine, 15
U.C.L.A.L. REV. 436, 437 (1968); Jonas, supra note 6, at 223-24.
11. W. PROSSER, HANBooK OF THE Liw OF TORTS 165-66 (4th ed. 1971).
[Vol. 25:604
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implications. Indeed, these different kinds of consent may address
issues that are not only distinct but opposite. For instance, in the
normal physician-patient relationship, the patient acts primarily out
out of self-interest, and the physician has no adverse interest that
might interfere with his or her judgment as to the appropriate treat-
ment for the patient. Society in such a case has only the attenu-
ated interest of preferring a healthy populace to an ill one. All of
these factors are altered to some degree in the context of experimen-
tation.12 The change in these considerations, therefore, should pro-
duce a corresponding change in the quantity and quality of the in-
formation an individual receives to enable him or her to decide
whether to consent to a suggested experimental procedure. This
modification should also condition the consequences of that deci-
sion, including the allocation of the costs. In the ordinary physician-
patient relationship, allowing the patient to bear the costs associ-
ated with nonnegligent injuries sustained as a result of consensual
treatment can be supported by 'the logical proposition that costs
should flow in the same direction as benefits. In the experimental
setting, however, placing the costs on the subject is less clearly justi-
fied, since most of the benefit is directed not to the subject but to
the research community and, ultimately, to society.
If consent does not shift cost-bearing to the subject, then, what
does it accomplish? From the perspective of the lawyer, who is ac-
customed to looking through the lens of liability, it might seem that
consent has no function if it does not, move the risk of monetary
loss. But this view results from treating as fact the fiction that
money damages can truly compensate an injured human being.
In reality, consent establishes who will endure the actual suffering
if an experiment results in pain and injury, experiences that cannot
be shifted after the fact.
That the function of consent and the compensation of injuries
in the context of medical experimentation have not received ade-
quate attention is at first surprising, since one of the primary rea-
sons for society's hesitancy to allow the use of human volunteers is
12. In the investigator-subject relationship, the primary purpose is to
gain knowledge; the direct benefit to the subject may be nil, minor,
or even beneficial, but is in any case subsidiary. The investigator
may or may not be a" physician; the subject may or may not be a
patient. In the former, the main objective is ,to secure knowledge;
in the latter, the welfare of the patient is the overriding considera-
tion. As stated initially, the former relationship may be character-
ized as a scientific alliance ....
Blumgart, supra note 6, at 255-56.,
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the significant probability of injury. One explanation for this lack
of attention may be society's unwillingness to acknowledge too di-
rectly its role in permitting one individual's life to be jeopardized,
even for the good of the many.' 3 This admission of the relative
worth of human life is seen by some as an erosion of the value
generally accorded human life in modem society. This reasoning,
however, can result in a paradox: we value the life of the individ-
ual so highly in the abstract that we refuse to face the task of valu-
ing it in the particular case.14 But avoiding the compensation issue
is not a rational mode of coming to terms with the decision to permit
the use of human volunteers in dangerous experimentation, once
that decision has been made.
This reaction, though, may be explained as a reflection of a
13. Congress recently enacted legislation establishing a Commission for
the Protection of Human Subjects of Biomedical and Behavioral Research.
National Research Service Award Act of 1974, Pub. L No. 93-348, tit. II,
§ 201, 88 Stat. 342. As first proposed in S. 2072, 93d Cong., 1st Sess. (1973),
the Commission was to have been charged with the task of developing "a
mechanism for the compensation of individuals and their families for injuries
or death proximately caused by participation of such individual in a biomedical
or behavioral research program." S. 2072, § 1202(a) (5). The Senate version
retained this responsibility. However, this specific charge was substituted in
CONF. REP. No. 93-1148, 93d Cong., 2d Sess. (1974), with the direction to the
Commission to "make recommendations to the Secretary [of HEW] . . . con-
cerning any other matter [in addition to administrative procedures necessary
to implement ethical guidelines in conducting research] pertaining to the pro-
tection of human subjects of biomedical and behavioral research." The Con-
ference Committee's treatment of the tenure and authority of the Commission,
which it reduced from 5 to 2 years and from regulatory to advisory, makes
clear the context of the elimination of specific reference to compensation.
Congress, at the urging of a majority of the House members, not only is un-
willing to confront squarely the role society plays in risking experimentation
subjects' lives, but also is unwilling to give up the beneficial results of such
activity.
14. This type of behavior has been christened the "Pompey syndrome" by
Edmond Calm in Drug Experiments and the Public Conscience, excerpted in
EXPERIMENTATION wrrH HuMAN BEINGS 184 (J. Katz ed. 1972). The phrase
is taken from Plutarch's description of Pompey on being told by a lieutenant
that the lieutenant would slit the throats of Antony, Caesar, and Lepidus,
guests on Pompey's ship, if Pompey granted him permission. Pompey regret-
fully refused permission, indicating he would have applauded the act which
would have left him sole ruler of the Roman empire if he could have avoided
the appearance of complicity. But, the lieutenant's action would have impli-
cated him. Similarly, Cahn suggests society would like to have the benefits
of research once completed without acknowledging the risks to which a fellow
human being was subjected to obtain that knowledge.
To the extent that Calabresi's concern is avoiding the appearance of "pur-
posive choices to kill individuals for the collective good," Calabresi, supra note
7, at 393, he may be said to partake of the Pompey syndrome.
[Vol. 25:604
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valid concern that compensation of injured volunteers might encour-
age questionable experimentation. 15 Society in general and the
professionals working in human experimentation in particular may
fear that making compensation available to injured volunteers might
become a license to undertake procedures not otherwise acceptable.
They have recognized that the problem is how to make two goals,
deterrence and just compensation,' 6 directly rather than inversely
related.
Indeed, another explanation of the scant discussion of compen-
sation in the literature on human experimentation may be the fail-
ure to distinguish between deterrence and the obligation to com-
pensate, although the interrelation of these concepts is the primary
dynamic in the fault system with which we are most familiar. As-
sessing costs to the party "at fault," the most common goal of tort
law, is a device well suited to sorting out costs among private par-
ties. When each party has equal ability to influence a source of
injury, charging costs to the one at fault both provides a source of
funds for compensation and serves as a deterrent to similar injuries
in the future. However, as the development of products liability
and the spread of other forms of strict liability indicate, traditional
liability based on fault does not achieve a proper distribution of re-
sponsibility when one of the private parties possesses greater control
over the sources of injury.17 Clearly, the ability to influence or
control sources of injury has been recognized as a reason for altering
society's scheme of assessment of injury costs on the basis of fault.
Medical experimentation presents another context in which the
traditional remedies that have evolved to redress wrongs between pri-
15. In dealing with a problem very similar to the one at hand-the choice
between expending resources on the rescue of a present, known accident victim
and devoting those resources to preventive measures to increase the statistical
chances of saving future lives-Charles Fried has urged that moral intuitions
be taken seriously and subjected to rational analysis to reveal their structures,
instead of being dismissed with the epithet "value judgment." Fried, The
Value of Human Life, 82 HARv. L. Rav. 1415, 1416 (1969).
16. Although the terms deterrence and compensation are here borrowed
from accident law, it should be noted that the question here presented is not
the normal one found in that context:
In medical experiments, much of this process [the indirect choice
of accident victims and .the indirect controls] seems reversed. It is
the lives to be saved by the experiment that seem future and conjec-
tural, while the life to be risked or taken is both present and real.
Most of the elements of fault are absent-the victim usually is sick
through no choice or fault of his own.
Calabresi, supra note 7, at 391.
17. See Prosser, The Assault Upon the Citadel, 69 YALB L.J. 1099 (1960).
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vate parties do not produce results that comport with our notions of
justice. The feeling that costs are not being properly allocated ap-
pears on the surface to be a reaction to the same considerations
that have resulted in the placing of costs on the manufacturers in
the products liability area. Closer examination, however, reveals
significant differences. The manufacturer has the ability not only
to produce nondefective products but also to spread the costs that
arise from the use of defective products. In a medical experiment,
however, the researcher is frequently engaging in the very research
that is necessary to refine his hypothesis. The experiment is the
equivalent of developmental tests in the manufacturing process. If
the hypothesis has not reached the experimental stage prematurely,
the researcher arguably cannot design a safer procedure. Fur-
ther, unlike the manufacturer, the researcher usually does not op-
erate in a market situation. Therefore the imposition of liability
without fault would not serve as an effective cost-spreading mech-
anism.
Although the rationales that support the doctrine of strict liabil-
ity are inapplicable to medical experimentation, still -the suspicion
persists that the costs of nonnegligent injury occurring in the course
of human experimentation are not justly allocated. What gives
rise to this suspicion? In what other ways does the injury arising
out of medical experimentation differ from a normal accident? One
answer is that society has allowed the researcher to expose the sub-
ject to a risk of substantial harm, not for the subject's benefit but
for its own. Since the aim is public benefit, our intuition is that the
untoward costs should not fall upon the individual, whether they re-
sult from the researcher's fault or not.
Clearly, the desire to compensate the victims of experimentation
should not eclipse concern for deterrence and control. The possibil-
ities of poorly designed or unwarranted experiments cannot be dis-
counted. Since it is obviously preferable to prevent injuries in medi-
cal experimentation entirely, considerable attention has been given
to deterrent measures that operate prospectively, such as review
committees.' 8 Unfortunately, such procedures do not constitute an
integrated control mechanism and do not contain devices designed
to recognize and compensate nonnegligent injuries. It is suggested
18. 45 C.F.R. §§ 46.1-.22 (1974) sets forth regulations that apply to insti-
tutions conducting research funded by the Department of Health, Education,
and Welfare. For a comprehensive analysis of the review committee as a con-
trol mechanism see Cowan, Human Experimentation: The Review Procedure
in Practice, 25 CASE W. RES. L. Rav. 533 (1975).
[Vol. 25:604
THE ROLE OF COMPENSATION
that only the addition of retrospective remedies can achieve these
goals. What is needed is a system that reweaves the common law
threads of control, deterrence, and compensation into a modern
pattern appropriate to the particular characteristics of human experi-
mentation.
HI. COMMON LAW THEORIEs
The pride and genius of the common law has been its enduring
flexibility. Repeatedly, as changes in society have given rise to
novel questions, the common law has resolved them through the ap-
plication of existing principles. 19 Nevertheless, as society has grown
more complex, courts have deferred to legislative solutions more fre-
quently. Sometimes this deference has been but a cue to the legisla-
tures to create statutory causes of action -to enable courts to act with
assurance in these new areas.2 0  In other instances, legislatures
have determined that the problems are better handled in adminis-
trative forums.2 1 At other times what has emerged is a pattern of
interrelated administrative and judicial action.22
19. As the legal profession began to recognize problems in the field of
medical experimentation generally and to consider possible solutions, the medi-
cal community questioned the appropriateness and competence of the law in
seeking such solutions. One response to this criticism came from then-Circuit
Judge Warren Burger, who pointed out that the role of the law in this area,
as in any other, is to mediate between those values inherent in the pursuit of
medical knowledge and the other values of society generally. "Science unre-
strained would be somewhat like an absolute mo-iarch-a great servant, but,
a terrible master. Law is inherently restraint. It is a restraint on science as
it is a restraint on kings, congresses and presidents, and none of them really
likes it very much. Those who become impatient with the slow pace of the
law's response to the needs of science must remember that the history of West-
ern philosophy shows that we cherish many values above scientific advances;
science must function within this framework." Burger, supra note 10, at 441.
20. Recognition of the right to maintain an action for invasion of privacy
is a good example of this. A strong theoretical argument for the recognition
of such a right had been developed in Warren & Brandeis, The Right to Pri-
vacy, 4 HARV. L. REv. 193 (1890). But the New York Court of Appeals, the
first state high court to be confronted with the problem, refused to recognize
the existence of the right to be left alone. Roberson v. Rochester Folding-
Box Co., 171 N.Y. 538, 64 N.E. 442 (1902). The state legislature reacted
to public indignation over Roberson by creating a statutory cause of action in
this area. Ch. 132, §§ 1-2, [1903] N.Y. Laws 308.
21. Workmen's compensation systems, discussed in notes 88-93 infra and
accompanying text, are an obvious example of such a determination.
22. The relationship among private arbitrators, the National Labor Rela-
tions Board, and the courts, which has emerged in the field of labor relations
within the jurisdiction of the NLRB in the past decade, is an example of such
amix.
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There are, however, two aspects of the common law mechanism
that recommend it as a system for compensating subjects injured in
the experimental context. The common law provides a retrospec-
tive remedy, thereby committing society's limited resources to the
resolution of only those problems that have actually arisen. Conse-
quently, where the common law or the common law bolstered by
statutory causes of action is sufficient to resolve new problems,
such a system brings about the most efficient expenditure of public
resources. In addition, the common law system of compensation
does not focus attention on society's decision to accept the risk of
injury inherent in the activity giving rise to liability. It has been
argued that the effect of the common law in the area of accident
law generally has been to mask the communal choice to prefer effi-
ciency to human lives. 23 If it could provide a means of sufficient
deterrence and adjust compensation in the experimental context,
then the common law system would also camouflage the decision
to accept the known risk to volunteers in exchange for some specula-
tive good, a major factor in society's uneasiness toward human ex-
perimentation in general. Therefore, before considering the im-
position of administrative structures to resolve the problems of in-
jury to human subjects, we should examine the potential of the
common law in the area.
A. The Types of Situations in Which Injuries Occur
There are three types of situations in which injury to subjects of
experimentation may occur. First, the common negligence of the
researcher-physician may cause injury to the volunteer. Secondly,
injury may arise in an experiment that should not have been con-
ducted in the first place. Experiments that fail to meet the prevail-
23. In the field of accidents, much of the control over the taking
of human life is accomplished by what economists call the market
Limbs and lives are given a money value; the activities that take lives
or limbs in accidents pay the victims; and people quite coldly decide
whether it is cheaper to install a safety device or to pay for the acci-
dents that occur because the safety device is missing. Despite the
enormous oversimplification of the foregoing example (the effect of
"fault" in determining accident payments, for instance, is ignored),
it indicates how "accidents" are controlled in an indirect fashion
which, nonetheless, takes into account both the values of the lives
taken and the cost of saving them.
The beauty of the market device is that no one seems to be mak-
ing the decisions to take lives and, therefore, no blatant infringement
of the commitment to human life as sacred occurs.
Calabresi, supra note 7, at 389-90.
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ing standards for approving the use of human volunteers2 4 or that
lack adequate consent of the subject 5 fall within the second cate-
gory. In such situations the injury complained of may or may not
relate to a defect in the execution of the experiment. Finally, in-
jury to the volunteer may occur notwithstanding the absence of
negligence, the appropriate approval of the experiment, and the sub-
24. The Nuremberg Code is generally viewed as stating the minimum re-
quirements to justify the use of human beings in experiments. Among the
principles of significance to the present considerations are:
2) The experiment should be such as to yield fruitful results for the
good of society, unprocurable by other methods or means of
study, and not random and unnecessary in nature.
3) The experiment should be so designed and based on the results
of animal experimentation and a knowledge of the natural his-
tory of the disease or other problem under study that the antici-
pated results will justify the performance of the experiment.
4) The experiment should be so conducted as to avoid all unneces-
sary physical and mental suffering and injury.
5) No experiment should be conducted where there is a priori rea-
son to believe that death or disabling injury will occurr ....
United States v. Brandt, 2 Trials of War Criminals Before the Nuremberg Mil-
itary Tribunals (The Medical Case) 181, 182 (Military Tribunal I, 1947)
(emphasis added).
25. In essence, the consent of the subject is merely one of the requisites
to a justifiable experiment. It has been accorded such significance, however,
as to merit separate treatment. In the present context, it can be distinguished
from the other essential elements, set out in note 24 supra, stated by the
Nuremberg Code by its extrinsic nature. The other factors inhere in the ex-
periment, whereas obtaining each subject's consent is an individual process by
which the same experiment will be viewed as justifiable with respect to one
subject (a consenting one) and unjustifiable with respect to another (a noncon-
senting one). The primary importance attached to this factor is evident from
the extended statement of the principle in the Nuremberg Code:
1) The voluntary consent of the human subject is absolutely essen-
tial.
This means that the person involved should have legal capacity
to give consent; should be so situated as to be able to exercise free
power of choice, without the intervention of any element of force,
fraud, deceit, duress, over-reaching, or other ulterior form of con-
straint or coercion; and should have sufficient knowledge and compre-
hension of the elements of the subject matter involved as to enable
him to make an understanding and enlightened decision. This latter
element requires that before the acceptance of an affirmative decision
by the experimental subject there should be made known to him the
nature, duration, and purpose of the experiment; the method and
means by which it is to be conducted; all inconveniences and hazards
reasonably to be expected; and the effects upon his health or person
which may possibly come from his participation in -the experiment.
The duty and responsibility for ascertaining the quality of the
consent rests upon each individual who initiates, directs or engages
in the experiment. It is a personal duty and responsibility which may
not be delegated to another with impunity.
United States v. Brandt, 2 Trials of War Criminals Before the Nuremberg Mil-
itary Tribunals at 181-82.
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ject's valid consent. Such unavoidable injuries are the specific un-
toward results that have given society pause in accepting human ex-
perimentation. 26
Where the negligence of the researcher-physician is the cause
of injury, the common law provides the universally accepted rem-
edy-an action for malpractice.2 7  To be sure, the experimental na-
ture of the main enterprise may make the recognition of negligence
in the traditional sense difficult. On the other hand, it is clear that a
subject's consent, as in the normal therapeutic situation, does not
relieve the researcher-physician of his common law duty of care. 28
Thus, even where consent is given, if the harm can be traced to the
researcher's error, the traditional remedy for negligence should pro-
vide the injured subject compensation.
B. Consent
In many cases harm will not be traceable to a negligent act;
the injured party might attempt to base a cause of action on the re-
searcher's failure to obtain the proper consent of the volunteer. The
victims of the Tuskeegee study, however, are the first injured sub-
jects to seek recovery on the explicit ground that free and informed
consent was not obtained. 29 Prior to this case, the courts appear
26. Another dimension that should be noted in charting an abbreviated
typology of situations in which a human subject may be injured in medical ex-
perimentation is that of the therapeutic versus the nontherapeutic situation. It
is beyond the scope of this article to deal with the gradations from the purely
therapeutic and nonexperimental situation to the experiment in which the goals
are wholly experimental and of no therapeutic value to the individual volun-
teer. The formulation of a workable definition of experimentation has been
addressed elsewhere. See, e.g., H. BEECHER, supra note 6, at 88-90; Moore,
Therapeutic Innovation: Ethical Boundaries in Initial Clinical Trials of New
Drugs and Surgical Procedures, 98 DAEDALus 502 (1969). For the purpose
of this article, the proposition that a procedure may be both experimental and
therapeutic is assumed. See generally 45 C.F.R. § 46.3(b) (1974). While
the two areas overlap, this article will also proceed on the premise that where
a procedure is both therapeutic and experimental, the latter characterization
controls.
27. W. PROSSER, HANDBOOK OF THE LAW OF TORTS 161-65 (4th ed. 1971).
28. 45 C.F.R. § 46.9 (1974) provides:
Any organization proposing to place any subject at risk is obligated
to obtain and document legally effective informed consent. No such
informed consent, oral or written, obtained under an assurance pro-
vided pursuant to this part shall include any exculpatory language
through which the subject is made to waive, or to appear to waive,
any of his legal right, including any release of the organization or
its agents from liability for negligence [emphasis added].
29. The Tuskegee Study case, a class action on behalf of all of the partici-
pants, both syphilitic group members and nonsyphilitic control group members
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not to have had the opportunity to distinguish the informed consent
required in the normal physician-patient relationship from the free
and informed consent required in the experimental situation.
Where the experimentation has offered some therapeutic benefit to
the subject, at least one court has ignored the experimental nature of
the activities in assessing the quality of information that the physi-
cian conducting research should supply in seeking a subject's con-
sent.3 0 In addition, the concept of consent in the normal therapeutic
situation is changing. An examination of two recent cases demon-
strates some of the difficulties surrounding the consent issue.
In Karp v. Cooley,31 a suit instituted by the widow of the recipi-
ent of the first mechanical heart, the court Tequired only the type
of consent obtained from the normal candidate for surgery, al-
though the physician himself was the developer of the experimental
device. 32  Plainly, the medical procedure in this case, though em-
ployed in a therapeutic setting, was experimental in the extreme.
Nevertheless, the court treated the experimenter-subject relationship
in the study, was recently settled out-of-court on what was to have been the
first day of trial in the civil suit. The settlement provided for individual mone-
tary awards not only for the syphilitic participants or their estates, but also
for members of the control group, N.Y. Times, Dec. 18, 1974, § 2, at
56, col. 4. The settlement with the nonsyphilitic participants or their estates
could be based only on the researchers' failure to obtain their informed con-
sent, since generally the nonsyphilitic participants received only benefits, e.g.,
free medical care, as a result of their participation.
30. Karp v. Cooley, 349 F. Supp. 827 (S.D. Tex. 1972).
31. Id.
32. The mechanical heart substitute was implanted after the patient's con-
dition deteriorated following heart surgery. The patient had signed a specially
prepared consent form which stated in part:
In the event cardiac function cannot be restored by excision of de-
stroyed heart muscle and plastic reconstruction of the ventricle and
death seems imminent, I authorize Dr. Cooley and his staff to remove
my diseased heart and insert a mechanical cardiac substitute. I un-
derstand that this mechanical device will not be permanent and ulti-
mately will require replacement by a heart transplant. I realize that
this device has been tested in the laboratory but has not been used
to sustain a human being and that no assurance of success can be
made.
349 F. Supp. at 831. The criteria that the court considered in determining
the sufficiency of this consent procedure are made clear in the opinion: "Upon
a review of all the evidence produced, it could not be concluded by a jury that
Dr. Cooley had violated the medical standard in this community by the infor-
mation he gave or did not give to Mr. Karp concerning his surgery." 349 F.
Supp. at 834 (emphasis added). That .the court did not consider appropriate
inquiry into the subject-patient's actual understanding of the experimental pro-
cedures to which he supposedly gave his consent is also made clear: 'Texas
law would require that a jury be instructed that Mr. Karp is charged with read-
ing the consent even if in fact he did not." 349 F. Supp. at 835.
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no differently than the normal physician-patient relationship. Given
the experimental nature of the situation, a determination whether
the procedure's potential for successful use in human beings had
been clearly indicated should have been put at issue even before
the question of the validity of consent was reached. The Cooley
court, however, did not perceive any material difference between the
case at bar and the normal therapeutic situation and never consid-
ered the threshold question.3 3  Not surprisingly, then, because the
court failed to recognize any difference between experimental and
accepted methods of therapy, it was content to leave the determina-
tion of the type and quality of information that should be given a
patient in an experimental, albeit therapeutic, setting to the attending
physician. Liability would be imposed only when the physician's de-
cision failed to conform to the standard of the "reasonable medical
practitioner. '3 4 This resolution of the consent issue is consistent
with the test employed by the majority of jurisdictions in assessing
the adequacy of information supplied in the normal physician-pa-
tient relationship. 35
Since the surgeon in Cooley was the developer of the experimen-
tal device employed, the court's limited scrutiny is especially dis-
turbing. A physician has a duty to his patient to choose .the best
treatment and so must balance the probable effectiveness of and the
dangers posed by the contemplated action. At the same time, the
researcher has a personal interest in establishing the efficacy of the
experimental device, procedure, or therapy that he has developed
33. The court's paraphrase of the issues raised by the plaintiff does not
make clear whether the question of the development of the procedure to a point
of readiness for human use was explicitly raised. The plaintiff generally ques-
tioned whether "under the circumstances the defendants were negligent in per-
forming the corrective surgery, implanting the mechanical heart, and submit-
ting the patient to the surgery for inserting the human donor heart. ... ." 349
F. Supp. at 832. The court interpreted this issue as questioning the treatment
chosen in view of the particular patient's condition, rather than as questioning
the appropriateness of the therapeutic use of the treatment at that stage of its
development.
34. In granting the defendants' motion for a directed verdict, the court
stated, "Upon a review of all the evidence produced, it could not be concluded
by a jury that Dr. Cooley had violated the medical standard in this community
by the information he gave or did not give to Mr. Karp concerning his sur-
gery." 349 F. Supp. at 834.
35. Annot., Malpractice: Physician's Duty to Inform Patient of Nature
and Hazards of Disease or Treatment, 79 A.L.R.2d 1028 (1961); Note, Re-
structuring Informed Consent: Legal Therapy for the Doctor-Patient Rela-
tionship, 79 YALE L.J. 1533, 1555-61 (1970).
[Vol. 25:604
THE ROLE OF COMPENSATION
or the hypothesis he seeks to prove. And yet, the court failed even
to mention this conflict of interest.
In contrast to the approach of the Cooley court, the United
States Court of Appeals for the District of Columbia has gone so far
as to reexamine the traditional standards for judging the adequacy
of information upon which informed consent is obtained in the
normal therapeutic situation. In Canterbury v. Spence"6 the plain-
tiff consented to a recognized and accepted treatment, but he had
not been told that the treatment resulted in injury in a small but
statistically predictable percentage of cases.37 Plaintiff's treatment
resulted in one of these statistically predictable injuries. The phy-
sician, however, attempted to justify his failure to inform the plain-
tiff of the risk on the ground that despite the remoteness of the
risk, the disclosure of such information might have caused the pa-
tient not to consent to the. needed treatment.38 The court noted
that prior to the treatment the patient had been suffering consider-
able but bearable back discomfort, whereas after the treatment the
patient was left partially paralyzed. In view of these facts, the
court strongly affirmed the patient's right to choose between bearing
his present known pain and bearing the risk of severe injury in-
volved in seeking the relief that might result from the treatment. To
make such a choice, the patient must be informed of all material
risks attendant to the proposed procedure. 39  Except in the most
unusual case, the court reasoned, the physician may not legally in-
form the patient of only selected risks. 40
The Canterbury court rejected the majority position that a phy-
sician need only inform a patient of those risks that other physicians
practicing in the community customarily reveal to their patients.
Since the foundation of the opinion was the patient's right to self-
determination, the court measured -the scope of the physician's duty
36. 464 F.2d 772 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972).
37. "Dr. Spence further testified that even without trauma paralysis can
be anticipated 'somewhere in the nature of one per cent' of the laminectomies
performed, a risk he termed 'a very slight possibility.'" 464 F.2d at 778.
38. 464 F.2d at 778.
39. The root premise is the concept, fundamental in American juris-
prudence, that "[e]very human being of adult years and sound mind
has a right to determine what shall be done with his own body .....
True consent to what happens to one's self is the informed exercise
of a choice, and that entails an opportunity to evaluate knowledge-
ably the options available and the risks attendant upon each.
464 F.2d at 790 (footnotes omitted).
40. 464 F.2d at 788-89.
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by the patient's need for information. 41 Liability for nondisclosure
would arise, however, only in situations where the knowledge of an
unrevealed material risk would have caused the patient to decide
against the therapy. The question whether the disclosure of the
unrevealed risk would have had such an effect on the patient's choice
is determined on the basis "of what a prudent person in the pa-
tient's position would have decided if suitably informed of all the
perils bearing significance."'4
2
Cooley and Canterbury represent the poles of present judicial
thought that would provide the backdrop of the common law in a
suit based on the failure to obtain adequate consent from an in-
jured subject of human experimentation. The approach taken in
Canterbury would very likely produce a more searching inquiry in
the experimental situation. If the Cooley court had applied the
Canterbury standard, it might have questioned the patient's ability
to consent without information on whether the experimental proce-
dure had been developed to a point where its readiness for use on
human beings was indicated. At the very least, Canterbury's rejec-
tion of the medical-community-standard test and the court's empha-
sis on the relationship of the particular physician to the particular
patient would have resulted in a more satisfying inquiry into the
physician's apparent conflict of interest in Cooley.4s
41. mhe patient's right of self-decision shapes -the boundaries of the
duty to reveal. That right can be effectively exercised only if the
patient possesses enough information to enable an intelligent choice.
The scope of the physician's communications to the patient, then,
must be measured by the patient's need, and that need is the infor-
mation material to the decision .... [A]U risks potentially affect-
ing the decision must be unmasked.
464 F.2d at 786-87.
42. 464 F.2d at 791.
43. Even under the majority standard expressed in Cooley, recent codifica-
tions of practices for obtaining consent of human volunteers in federally
funded research should be strong evidence of what a reasonable researcher-
physician would have revealed to the subject in circumstances similar to the
Cooley situation today. An example of such official requirement is 45 C.F.RL
§ 46.3(c) (1974), which provides:
"Informed consent" means the knowing consent of an individual or
his legally authorized representative, so situated as to be able to exer-
cise free power of choice without undue inducement or any element
of force, fraud, deceit, duress, or other form of constraint or coercion.
The basic elements of information necessary to such consent include:
(1) A fair explanation of the procedures to be followed, and their
purposes, including identification of any procedures which are
experimental;
(2) a description of any attendant discomforts and risks reasonably
to be expected;
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In the most widely known incidents that have raised the public's
concern about human experimentation, consent, as a practical mat-
ter, has been totally lacking.44 The common law requirement of
consent, whether measured by the majority standard as set out in
Cooley or by the Canterbury standard, would seem to provide re-
lief in such cases where injury has resulted. More difficult prob-
lems arise when injury occurs in the context of experimentation and
consent, as defined in the therapeutic setting, has been granted.
The question then becomes whether there is a need to distinguish
consent given in the experimental situation from that given in the
course of normal therapy.
The limitations on liability in the therapeutic setting serve to il-
lustrate the role of consent given in the ordinary physician-patient
relationship. Even under the more liberal Canterbury test, there
are two major qualifications to availability of relief. There must be
an injury, and the failure to place the injured party in a position to
give informed consent must be the cause of that injury. 45 If the fact-
(3) a description of any benefits reasonably to be expected;
(4) a disclosure of any appropriate alternative procedures that
might be advantageous for the subject;
(5) an offer to answer any inquiries concerning the procedures; and
(6) an instruction that the person is free to withdraw his consent
and to discontinue participation in the project or activity at any
time without prejudice to the subject.
Moreover, in any research conducted in institutions subject to disclosure and
consent requirements, a subject's private cause of action for injury in an experi-
ment where consent was obtained without full disclosure of material risk
should be recognized as a statutory tort. 45 C.F.R. § 46.5(a) (1974) requires
that organizations that have projects funded by the Department of Health, Edu-
cation, and Welfare and involving human subjects file general assurances of
ongoing review and implementation procedures in accordance with 45 C.F.R.
§ 46.6 (1974). 45 C.F.R. § 46.6(a) (1974) speaks of the organization's
"statement of principles which will govern the organization in the discharge
of its responsibilities for protecting the rights and welfare of subjects." The
context of this section implies strongly that the required statement of principles
is not limited in its application to subjects in HEW funded research, but should
extend to all subjects in the organization's research activity, regardless of
source of funding. Therefore, since he or she would be a member of the class
which the regulations are designed to protect, the injured subject should be per-
mitted to recover on the basis of a statutory tort. Cf. Griffin v. United States,
351 F. Supp. 10 (E.D. Pa. 1972).
44. See note 2, supra.
45. No more than breach of any other legal duty does nonfulfillment
of the physician's obligation to disclose alone establish liability to the
patient. An unrevealed risk that should have been made known must
materialize, for otherwise the omission, however unpardonable, is le-
gally without consequence.. . . And, as in malpractice actions gen-
erally, there must be a causal relationship between the physician's
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finder decides that a prudent person, given the information the in-
jured patient did not have, nonetheless would have consented to the
procedure, there is no liability under Canterbury. Because the pa-
tient is the major beneficiary in the normal therapeutic situation,
these limitations are understandable. The treating physician and
the patient have the same basic objective-achieving relief and re-
covery. Where the limitations contained in Canterbury operate to
deny relief, notwithstanding the failure to provide the patient with
all of the material facts, plaintiffs uncompensated burden may be
viewed as a justifiable -trade-off for -his or her anticipated benefit.
Moreover, since the aim of the physician and the patient is to bene-
fit the patient only, it is not likely that -the physician's judgment Will
be clouded by any interests not shared by the plaintiff. Therefore,
in the normal therapeutic situation the primary function of consent
is to allow the patient to determine what will be done to his or her
body; the deterrent effect of consent is negligible.
The possibility of researcher conflict of interest in the experi-
mental context, however, greatly increases the role of consent as a
deterrent. The researcher should not be permitted to select the
risks that he or she deems it advisable to reveal to a subject; nor
should the fact-finder be charged with deciding whether a "pru-
dent person," even if provided with the undisclosed material infor-
mation, would have consented to the experiment. 46 These limita-
tions clearly diminish the measure of control that the requirement of
full and informed consent is capable of providing. Such a result
is inappropriate in the experimental situation where, unlike the
therapeutic situation, -the interests of researcher and subject may con-
flict and the major benefits of the endeavor flow not to the subject
but to society. These distinguishing features indicate that more con-
trol is needed in the experimental context than in the therapeutic
context. 47
failure to adequately divulge and damage to the patient.
464 F.2d at 790.
46. Cf. Note, Restructuring Informed Consent: Legal Therapy for the
Doctor-Patient Relationship, 79 YALE U. 1533, 1563 (1970).
47. So that the control feature of the consent requirement is fully utilized
and so that subjects are adequately protected, failure to make full disclosure
of the known risks to the subjects in human experimentation should be action-
able per se when injury has resulted. Inquiry should not be made
whether the subject would have consented if full information had been given.
Whether there should be a private cause of action where consent was not based
on full information, but injury has not occurred-perhaps largely an academic
question-raises the problem of windfall to the subject. A more appropriate
remedy for such a failing would be administrative review of the researcher's
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In addition, because it has developed in the therapeutic setting,
the present common law concept of consent does not address an im-
portant problem inherent in human experimentation. The com-
mon law requirement of consent contemplates the disclosures of
known risks only.48 The Canterbury case, which advocates the
broadest consent requirement, would seem to impose liability for a
failure to make disclosure of the general possibility of unknown
risks. 49 In the experimental situation, however, the unknown risk is
the greatest source of potential injury. Consequently, a subject
who consents to experimentation with the specific knowledge that
injury may result from an unknown risk and who suffers harm from
such a cause would not be afforded a remedy under the present
common law concept of consent.
The common law should begin to take into account the differ-
ences between the purpose of consent in the normal physician-pa-
tient relationship and the purpose of consent in the context of hu-
man experimentation. If such a development took place, the com-
mon law would acquire the capacity to address more of the prob-
lems that arise from experimentation. The basic issue in experi-
mentation cases should be the validity of the injured subject's con-
sent. The threshold question, then, would be the ability of the sub-
ject to consent. Since the concept of free and informed consent can
be viewed as creating an exception to the general rule of incapacity
to consent to serious battery, attention should be focused on the
question whether the particular experiment met the basic criteria
justifying the use of human subjects.5 9 A subject's consent should
be viewed as void and not within the exception in cases where the
experiment did not meet such criteria. 51
Furthermore, development of the common law in this area would
actions with appropriate sanctions imposed. See, e.g., Board of Regents of
Univ. of St. of N.Y., Licenses Suspended, Suspensions Stayed, Respondents
Placed on Probation, 34 J. MEETING OF BOARD OF REGENTS OF UNIv. OF ST. OF
N.Y. 787 (1965). In this case there was no indication of any permanent physi-
cal harm resulting from the injection of cancerous cells into subjects who were
ill with diseases other than cancer. However, despite the absence of proof of
physical harm to the research subjects who rejected the cells, the two physician-
researchers bad their licenses to practice medicine suspended.
48. See note 39 supra and accompanying text.
49. Since Canterbury requires the disclosure of all known material risks,
the statistically predictable injury rate from unknown risks must be pointed out
to the subject. Notes 39-40 supra and accompanying text.
50. See note 54 infra and accompanying text.
51. This is, perhaps, only another way of viewing the warranties made
when a researcher solicits human volunteers.
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provide remedies for injured subjects whose consent was not based
on all the information available at the time the experiment be-
gan. 52  If the concept of consent were expanded in this manner,
the imposition of personal liability on the researcher would also in-
sure that every effort would be made to be certain that the subject
fully understood the risks that he or she was assuming. Such lia-
bility would complement the systems of prospective controls that
have been developing in recent years, 58 guaranteeing that these pro-
visions would be substantive rather than formal.
But even if existing doctrines were expanded, the common law
concept of consent would not hold promise as a means of compensat-
ing victims of unknown risks in human experimentation. The cen-
tral component of the consent doctrine is the duty to disclose.
Therefore, the imposition of liability on a consent theory for inju-
ries due solely to unknown risks would have to be based on the
failure prior to the experiment to provide information which, in
fact, the experiment itself generated. The courts justifiably would
resist stretching the concept of consent so far. Thus, it is neces-
sary to ascertain whether some of the newer theories of liability in
which negligence is not an element of the cause of action are trans-
ferable to the area of human experimentation.
C. Warranty and Strict Liability
The second common law concept that appears to promise relief
in some situations where human volunteers have been injured is
warranty. An express warranty, first of all, may arise from the
review procedures currently being followed in some institutions.
When an experiment using human beings is submitted for review
prior to commencement, three broad requirements should have been
met: (1) the proposed research must have been advanced as far
as possible through the use of laboratory animals and techniques
not placing human beings at risk; (2) the results of these efforts
should indicate a sufficient probability of benefit to justify proceed-
ing to the stage of human experimentation; 54 and (3) the researcher
must have taken due care in the planning of the experiment to
eliminate avoidable risks. The submission of the experiment to the
review committee should be viewed as a personal express warranty
52. See note 46 supra and accompanying text.
53. See generally 45 C.F.R. §§ 46.1-.22 (1974); National Research Serv-
ice Award Act of 1974, Pub. L. No. 93-348, 88 Stat. 342.
54. See notes 24, 25 supra.
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by the researcher that these conditions have been fulfilled. Simi-
larly, the approval of the review committee should be taken to be
an express warranty by the institution that the requirements have
been met. Even where no review is required or obtained, the de-
cision to conduct the experiment should be held to give rise to an
implied warranty of fulfillment of the three prerequisites. When a
volunteer is injured in an experiment that does not in fact meet
these specifications, both the approving institution and the individual
researchers should be held liable for breach of their waranties. Al-
ternatively, liability could be based on negligence of these parties
for wrongly approving and continuing such a project.
Though it is clear that the principles of warranty can be applied
to medical experimentation, it is more difficult to determine to what
extent the related concept of enterprise liability55 can be employed
to compensate injured volunteers and to control the experimental
use of human beings. Several recent lines of cases give guidance
in this area and also indicate how likely the courts are to find such
liability in medical experimentation.
One series of cases addresses the problems arising from transfu-
sions of infected blood. In the course of medical treatment a pa-
tient may get a transfusion that causes severe injury or death, when
the blood serum has been donated by or purchased from an indi-
vidual with hepatitis. The current state of medical knowledge has
provided no completely accurate, method to detect the presence of
hepatitis infection in blood available for transfusion. 56 Formerly, if
the blood bank, hospital, and medical personnel had used all avail-
able procedures for detecting these elements, courts did not hold
them liable for injuries sustained when transfusions did result in pa-
tients contracting hepatitis. Recently, however, the leading case for
nonliability of such parties, Perlmutter v. Beth David Hospital,5" has
been rejected by several courts.
55. As used in this article, this term indicates the principle of distributing
the total costs of developing products and services evenly through the popula-
tion that benefits from their availability. It is broader in significance than
normal products liability theory in explicitly attempting to postulate cost-
spreading mechanisms where there may not be an ultimate product or service
to facilitate cost-spreading procedures.
56. Recent developments in testing for the presence of hepatitis virus in
blood available for transfusions have increased to 35 percent the capacity to
detect the virus. N.Y. Times, Apr. 17, 1974, at 24, col. 6. See also Franklin,
Tort Liability for Hepatitis: An Analysis and a Proposal, 24 STAN. L. REV.
439, 444 (1972).
57. 308 N.Y. 100, 123 N.E.2d 792 (1954).
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In Perlmutter, major reliance was placed on characterization of
the blood -transfusion as a service rather than a sale. This dis-
tinction allowed the court to find that there was no attendant im-
plied warranty of any kind under the Sales Act. The service char-
acterization of Perlmutter was first rejected in Cunningham v. Mac-
Neal Memorial Hospital,5" which flatly held the blood transfusion
in that case to be a sale, which gave rise to strict liability in tort. 59
In reaching this conclusion, the court analyzed section 402A of the
Restatement (Second) of Torts, which places on the seller liability
for injuries caused by a defective product. 60 Moreover, the court
rejected defendant's argument that the hepatitis-infected blood came
within -the exception that comment K of section 402A creates for
unavoidably dangerous products. 61 It interpreted this exception to
58. 47 I1. 2d 443, 266 N.E.2d 897 (1970).
59. Id. at 452, 266 N.E.2d at 902.
60. REsTATEMENT (SEcoND) OF ToRTs § 402A (1965) provides:
(1) One who sells any product in a defective condition unreason-
ably dangerous to the user or consumer or to his property
is subject to liability for physical harm thereby caused to the
ultimate user to consumer, or to his property, if
(a) the seller is engaged in the business of selling such a
product, and
(b) it is expected to and does reach the user or consumer
without substantial change in the condition in which it is
sold.
(2) The rule stated in Subsection (1) applies although
(a) the seller has exercised all possible care in the preparation
and sale of his product, and
(b) the user or consumer has not bought the product from or
entered into any contractual relation with the seller.
This section, which was adopted by the American Law Institute in 1964, has
been interpreted both as a reaction to the difficulties that injured consumers
faced in proving where the negligence which was the cause of injury had oc-
curred in the chain of supply and as an effort to distribute the total of the
expected cost associated with the use of a product through the consuming pub-
lic.
In Cunningham, the emphasis of the decision was not based upon the ap-
plicability of either of the above policies to the situation of transfusion-related
hepatitis, but rather upon characterization of the provision of blood by the hos-
pital as a sale, which triggered the application of § 402A.
61. Comment k to § 402A provides:
There are some products which, in the present state of human knowl-
edge, are quite incapable of being made safe for their intended and
ordinary use. These are especially common in the field of drugs.
An outstanding example is the vaccine for the Pasteur treatment of
rabies, which not uncommonly leads to very serious and damaging
consequences when it is injected. Since the disease itself invariably
leads to a dreadful death, both the marketing and the use of the vac-
cine are fully justified, notwithstanding the unavoidable degree of risk
which they involve. Such a product, properly prepared, and accom-
panied by proper directions and warning, is not defective, nor is it
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apply only to pure products and held that the blood in this case was
not pure when sold to the patient, because it contained the hepati-
tis infection.
Cunningham has been criticized for its mechanical application of
strict liability under section 402A, on the ground that it allowed a
major policy decision to rest on an act of judicial labelling. 62 Two
other courts that have rejected the Perlmutter rationale have at-
tempted to deal more directly with the policy choices involved. The
Pennsylvania Supreme Court in Hoffman v. Misericordia Hospital of
Philadelphia6 3 recognized that implied warranties of merchantability
and fitness for a particular purpose can arise in nonsales transactions.
Moreover, the decision suggested strongly that recovery would be
based on contract principles of warranty rather than on tort princi-
ples. However, although the court alluded to the policy questions
left unanswered by Cunningham, it did not discuss them fully, be-
cause the case was before the appellate court on the issue whether
defendant's demurrer should be sustained.
The policy questions were addressed directly by a New Jersey
court in Brody v. Overlook Hospital,6 4 which discarded the judicial
immunity created by Perlmutter in favor of strict liability in tort.
The court reasoned that strict liability would force hospitals to
choose suppliers whose collection practices were least likely to re-
sult in gathering contaminated blood and would encourage them to
take more active roles themselves in screening donors. 5 Essen-
unreasonably dangerous. The same is true of many other drugs, vac-
cines, and the like, many of which for this very reason cannot legally
be sold except to physicians, or under the prescription of a physician.
It is also true in particular of many new or experimental drugs as
to which, because of lack of time and opportunity for sufficient medi-
cal experience, there can be no assurance of safety, or perhaps even
of purity of ingredients, but such experience as there is justifies the
marketing and use of the drug notwithstanding a medically recogniz-
able risk. The seller of such products, again with the qualification
that they are properly prepared and marketed, and proper warning
is given, where the situation calls for it, is not to be held to strict
liability for unfortunate consequences attending their use, merely be-
cause he has undertaken to supply the public with an apparently use-
ful and desirable product, attended with a known but, apparently rea-
sonable risk.
62. See Franklin, supra note 56, at 461; Note, Strict Liability for Disease
Contracted from Blood Transfusions, 66 Nw. U.L. Rav. 80, 87 (1971).
63. 439 Pa. 501, 267 A.2d 867 (1970).
64. 121 N.J. Super. 299, 296 A.2d 668 (Super. Ct. 1972).
65. The blood banks stand in the same position to the hospital as the
manufacturer of a product does to a distributor-as a supplier to a
marketer. It can be anticipated that adoption of a strict liability
standard for the State of New Jersey will have the beneficial effect
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tially admitting that these efforts on the part of hospitals would at
best only reduce the incidence of liability, the court went on to en-
dorse strict liability as a loss-spreading device.86
As in the blood serum cases, an unavoidable injury in a medi-
cal experiment gives rise to a clash between the law's growing ten-
dency to impose costs on the activities that produce ,them and the
notion that the healing professions should be held liable only for
fault.67  Just as some courts have found hepatitis-infected blood to
be defective, focusing on the result of its use and not on what physi-
cians could know at the time of its administration, so they could
hold experiments that in fact cause injury to be defective. It is pos-
sible, however, to distinguish the medical experimentation situation
from the blood serum cases on the basis of foreseeability in a nar-
row sense. In the blood serum cases, the risk of hepatitis is specifi-
cally anticipated. To some extent, altered collection procedures can
remedy the problem. The most troublesome risks of medical experi-
mentation, however, are those that are totally unforeseeable. What
significance, then, should this distinction have?
The issue of liability for unforeseeable consequences has been
treated in a series of cases. The central problem is to determine the
warrantor's responsibility when he sells a product that despite appro-
priate manufacture and use causes injury to a significant portion of
its consumers. The two leading cases in this area are Green v.
American Tobacco Co.68 and Pritchard v. Liggett & Myers To-
of forcing hospitals to deal only with those blood banks which have
good safety records, thus decreasing the risk of the patient's becom-
ing infected with hepatitis as a result of a transfusion.
Even in the comparatively low number of cases in which the hos-
pital has recourse to only a single blood bank, imposition of strict
tort liability may well spur the hospital to take a more active role
in influencing the bank's collection processes, i.e., more careful
screening of donors. Most importantly, the imposition of strict liabil-
ity cannot help but force hospitals both to supervise more carefully
their own use of blood, and to encourage medical research to develop
either a more satisfactory test for hepatitis or an immunization vac-
cine to be given against the disease to a patient about to undergo a
transfusion.
Id. at 307.08, 296 A.2d at 672-73.
66. "Another important policy justification for strict liability is that of
'loss spreading.' If the hospital bears the loss resulting from hepatitis-infected
blood, it will tend to spread the loss among all parties, i.e., donors, blood
banks, perhaps its patients." Id. at 308, 296 A.2d at 673.
67. Franklin, supra note 56, at 472, 476.
68. The litigation of this case spanned 12 years, including seven stages.
After the case was filed in 1957, there was a jury trial in the United States
District Court for the Southern District of Florida in which a general verdict
was returned for the defendant on the basis of the answers to four written in-
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bacco Co.6 9 In Green, the Florida Supreme Court held that the
consumer was entitled to rely on implied ,assurances that cigarettes
were wholesome and found that the manufacturer could be held ab-
solutely liable for a consumer's death from cancer caused by smok-
ing cigarettes.7 0
Although by the time of trial the causal connection between
smoking and lung cancer had been demonstrated, it was unknown at
the time plaintiff purchased and smoked the cigarettes that allegedly
caused his death from cancer. Therefore the case turned on
terrogatories. Briefly, the interrogatories indicated that the jury believed the
plaintiffs husband had died of lung cancer, a proximate cause of which was
the smoking of defendants' product, Lucky Strikes. However, the jury also
found that the defendant could not by "reasonable application of skill and hu-
man foresight" have known of the carcinogenic effects of its product.
At the first hearing in appellate court, 304 F.2d 70 (5th Cir. 1962), the
jury's verdict was upheld. However, on petition for rehearing, 304 F.2d 85
(5th Cir. 1962), the court agreed to certify to the Supreme Court of Florida,
under its procedure allowing it to render advisory opinions to federal courts
faced with novel questions of Florida law in diversity cases, the question of a
manufacturer's liability absent the foreseeability of the harm which its product
could cause.
The Supreme Court of Florida responded in 154 So. 2d 169 (Fla. 1963),
that the United States Court of Appeals had misinterpreted Florida law on the
issue of manufacturer liability absent foreseeability. The manufacturer's op-
portunity for knowledge of a defect causing an injury to a customer was irrele-
vant to his liability. On the basis of the Florida court's interpretation, the
original jury verdict was overturned and a new trial ordered by the federal ap-
pellate court, 325 F.2d 673 (5th Cir.), cert. denied, 377 U.S. 943 (1963).
In the second jury trial in 1964, the defendant produced expert witnesses
who testified, over plaintiffs objection, that the cause of lung cancer was un-
known and that research had not established a fundamental link between cig-
arettes and cancer. In assessing the credibility of the expert witnesses for each
side, the jury apparently believed the defendant's and rendered a verdict ac-
cordingly.
On appeal, a three-judge panel for the United States Court of Appeals for
the Fifth Circuit reversed the jury verdict and rendered judgment for the plain-
tiff, notwithstanding the verdict. 391 F.2d 97 (5th Cir. 1968). The majority
held that the question of causation had been foreclosed by the first jury finding
and it was error to have submitted the issue of causation and evidence on the
point to the jury.
Finally, the Fifth Circuit agreed to reconsider en banc the reversal of the
second jury verdict, 409 F.2d 1165 (5th Cir. 1969). The majority of the court,
sitting en banc, overruled the three-judge panel, holding the evidence on causa-
tion was admissible at the second trial and reinstating the jury verdict for the
defendant. However, this action theoretically did not affect the Florida com-
mon law on manufacturers' liability despite lack of opportunity for knowledge
of a product's defect.
69. 350 F.Zd 479 (3d Cir. 1965).
70. 154 So. 2d at 170-71.
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whether liability should be imposed for breach of an implied war-
ranty when -the manufacturer or warrantor could not by reasonable
application of human skill and foresight have known of the dan-
ger.7' The court concluded that a manufacturer's or seller's ac-
tual knowledge or opportunity for knowledge of a defective or un-
wholesome condition was completely irrelevant to the issue of lia-
bility on the theory of implied warranty. The court said: "The
contention that the wholesomeness of a product should be de-
termined on any standard other than its actual safety for human
consumption when supplied for that purpose, is a novel proposition
in our law, and one which we are persuaded has no foundation in
the decided cases."'72
In Pritchard, the second tobacco case, the plaintiff brought an
action for personal injury alleging that 'he had contracted lung can-
cer as a result of smoking cigarettes. The defendant pleaded
assumption of the risk and contributory negligence as affirmative de-
fenses to plaintiff's claim of breach of implied warranty. As in
Green, the central question was foreseeability, but in this case the
specific issue was whether a consumer could be held to have as-
sumed an unforeseen risk. The court stated that a person who vol-
untarily exposes himself to a danger of which he has knowledge or
notice assumes the attendant risk. However, the court held that
since contributory negligence is not available as a defense in an ac-
tion for personal injury based on breach of warranty, assumption of
the risk is likewise not available. 73 Thus, in the case of the unfore-
71. 154 So. 2d at 170; 391 F.2d at 100.
72. 154 So. 2d at 173, quoted in 391 F.2d at 105. A possible qualifica-
tion of the Green doctrine regarding foreseeability is given in the case of
Caputzal v. Lindsay Co., 48 N.J. 69, 222 A.2d 513 (1966). This was an ac-
tion by the purchaser of a water softener against the manufacturer for injury
allegedly resulting from drawing water from the faucet. The machine malfunc-
tioned and caused the water to take on a rusty color. The plaintiff, upon see-
ing the color of the water, feared that he had been poisoned and had a heart
attack. The court held that even if the device was so defective as to cause
the rusty color, the plaintiff's attack, caused by fright at the sight of the water,
was an extraordinary occurrence not reasonably foreseen in the normal person.
It was an idiosyncratic reaction and defendant therefore was not liable for its
consequences. The court did intimate that if the defendant had had notice of
the idiosyncracy, it probably would have held defendant liable for the injury.
Thus, Caputzal formulates a rule concerning individual differences in reaction
and not one about the problem of foreseeability of the possible effects of a
product. Because of this difference in direction it would appear that the Green
rule is the accepted one on the general problem of foreseeability.
73. 350 F.2d at 485-86.
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seen danger it is the manufacturer who must bear the risk and not
the consumer.
Unlike the cigarette manufacturer, however, the medical re-
searcher will seldom have warranted that his procedure is harmless.
The very nature of his activity argues against implying any such
warranty, since it is the researcher's purpose in conducting the ex-
periment -to find out whether the procedure is safe and effective.
Because it is impossible for a researcher to warrant that the very
treatment he is testing is harmless, application of the principles of
warranty appears ineffectual as a method of shifting the costs of ex-
perimentation from its victims.
Although we react strongly to placing experimental costs on the
subject, we cannot deny that the unforeseen injuries resulting from
experimentation differ from those that have justified reallocation of
costs in other areas of tort law. In the cases concerning hepatitis-in-
fected blood, the imposition of liability could be justified because it
created an additional incentive to solve a definable problem. The
variety of injuries that could occur in medical research using human
beings, however, is as great as the number of individual experi-
ments, and there is no single identifiable source of injury that can
be attacked. As a device for directing the efforts of researchers and
controlling their conduct, therefore, strict liability is likely to be in-
effective.
Enterprise liability may make more sense, though, when its po-
tential as a cost-spreading mechanism is considered.7 4  If presently
evolving explicit control devices are working properly, any control
effect of imposing strict liability would duplicate these review pro-
cedures in any event. The primary result of imposing strict liabil-
ity, therefore, would be to shift the costs of injury in medical ex-
perimentation from the individual volunteer to the group or institu-
tion performing the experiment. Such loss-spreading, however,
might lead to the curtailment of important research, and it seems
clear that society does not want such a result, having placed a high
74. Recent developments in the concept of products liability generally in-
dicate a shift in emphasis from deterrence to cost-spreading. The California
Supreme Court and a New Jersey intermediate appellate court have rejected
the REsrATEMENT (SEcoND) OF ToaTs § 402A (1965) criterion that the defect
in a product must make it "unreasonably dangerous before liability will be im-
posed." Cronin v. J.B.E. Olson Corp., 8 Cal. 3d 121, 501 P.2d 1154, 104 Cal.
Rptr. 433 (1972); Glass v. Ford Motor Co., 123 N.J. Super. 599, 304 A.2d
562 (Super. Ct. 1973); cf. Brody v. Overlook Hosp., 121 N.J. Super. 299,
296 A.2d 668 (Super. Ct. 1972) (discussed at text accompanying note 64 su-
pra).
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priority on advancing medical knowledge. But even if some
means is devised to assure that research is not drastically cut back,
the imposition of liability in medical experimentation, though it
will relieve the individual of the cost of society's priorities, will not
necessarily reduce the number of injured volunteers.
Even if courts were ready to apply strict liability in some cases
involving medical experimentation, it is unlikely that they would
adopt it, at least initially, in all situations. Some courts, moving in
the direction of strict liability, would probably look for some trans-
action from which a warranty could be implied, whether sale or
provision of services, as most courts dealing with the blood serum
cases have done. The case of pure experimentation would pose dif-
ficulties in this regard, precisely because there is no promise of bene-
fit to the volunteer. As mentioned above, no representation-
express or implied-is made in such a situation as to the value of the
procedure to the individual. No service is rendered. In fact, it is
the volunteer who is rendering the service, and the safety of the pro-
cedure is usually explicitly disclaimed. The same is often true in the
experiment with a subject for whom some beneficial result is ex-
pected, but in such a case the service nature of the transaction would
provide the opportunity for a court to apply strict liability under
Hoffman,75 if it were so inclined. This could lead to the anomalous
result of making relief available to injured subjects who had expected
some benefit from the experiment but not to those who incurred un-
necessary risks for the benefit of society.
Although some courts have overcome their reluctance to go be-
yond fault as a basis for liability in cases related to medicine, it
would be premature to speculate that the development of strict lia-
bility in all medical contexts will parallel that in the blood serum
cases. Several courts have explicitly rejected invitations to carry
products liability theory into cases relating to the medical profession
generally. In Magrine v. Krasnica,76 for example, the plaintiff
sought recovery on the theory of products liability against a dentist
for an injury incurred because of a defective hypodermic needle.
In this case, the plaintiff was injured when the needle separated
from the syringe and became embedded in her jaw. The defendant
testified that he did not know why the needle had broken or from
75. 439 Pa. 501, 267 A.2d 867 (1970). See generally text accompanying
note 63 supra.
76. 94 N.J. Super. 228, 227 A.2d 539 (Hudson County Ct. 1967), alt d
sub nom. Magrine v. Spector, 100 N.J. Super. 223, 241 A.2d 637 (Super. CL
1968), aff'd per curiam, 53 N.J. 259, 50 A.2d 129 (1969).
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whom he had purchased it, but he did know the manufacturer. The
trial court rested its judgment for the defendant on two grounds:
First, the doctrines behind products liability did not support its ex-
tension to cover the dentist in this situation,7" and secondly, the
state's malpractice law expressed a public policy to impose liability
on doctors only for their negligence. 78 The intermediate appellate
court affirmed on the basis of the former reasoning only, over a
strong dissent. 79 The New Jersey Supreme Court affirmed both the
trial court's and the intermediate appellate court's opinions and rea-
soning, not seeming to recognize any difference between them.80
Two California courts have read Magrine approvingly as stand-
ing for the proposition that a physician should not be viewed as
standing in the same position as the retailer of the instruments he
uses or the drugs he prescribes. 81 Rather, these courts have sug-
gested, a doctor's situation is analogous to that of the consumer in a
normal retail transaction.82 However, because these cases rely on
the characterization of the physician and hospital as mere users of
defective products in their essentially therapeutic relationship to the
patient, they are not strong authority for resisting the application
of strict liability for injuries to experimental subjects. To the extent
that such injuries result from the basic choices that the researcher
makes in designing the experiment, it is the researcher who posses-
ses the power to control and the superior ability to know of dan-
gers, the attributes that are the foundation for the application of
strict liability to manufacturers. It is the researcher who constructs
the basic hypothesis of an experiment. Thus, unlike the doctor in
the therapeutic context, he is not a mere consumer and should not
be treated as one.
77. 94 N.J. Super. at 233-39, 227 A.2d at 542-46.
78. Id. at 240, 227 A.2d at 546.
79. 100 N.J. Super. 223, 241 A.2d 637 (Super. Ct. 1968).
80. The per curiam decision read in whole:
The judgment appealed from is affirmed substantially for the reasons
expressed by Judge Lynch, 94 N.J. Super. 228, 227 A.2d 539 (City
CL 1967), and in the majority opinion of the Appellate Division, 100
N.J. Super. 223, 241 A.2d 637 (App. Div. 1968).
53 N.J. 259, 250 A.2d 129 (1969).
81. Silverhart v. Mount Zion Hosp., 20 Cal. App. 3d 1022, 98 Cal. Rptr.
187 (Ct. App. 1971); Carmichael v. Reitz, 17 Cal. App. 3d 958, 95 Cal. Rptr.
381 (CL App. 1971).
82. Silverhart v. Mount Zion Hosp., 20 Cal. App. 3d at 1026-27, 98 Cal.
Rptr. at 190-91, extended the Magrine reasoning that only negligence should
be the basis of liability for injury from faulty instruments or drugs in the medi-
cal profession to include hospitals.
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Perhaps the most significant lesson to be learned from the cases
concerning hepatitis-infected blood transfusions is how legislatures
react to the imposition of liability on the medical profession on
other than a traditional fault basis. Since Perlmutter, a widely
criticized split decision, which raised the spector that courts not per-
suaded by the Perlmutter rationale could base liability on implied
warranty, 41 states have enacted statutes for the purpose of limiting
the scope of liability to negligence in similar situations.83 This legis-
lative response suggests that judicial recognition of strict liability for
medical experimentation would not be the final chapter in providing
compensation to injured victims. After juries returned large ver-
dicts in a few cases, the well-organized medical lobby could be ex-
pected to prevail upon the legislature to reject strict liability in this
area. In any event, even if strict liability became the rule, the basic
issue of benefit would distinguish the patient injured by a transfusion
of infected serum from the volunteer in a medical experiment. With-
out the implementation of some new system of liability, many of
those injured in experiments would have to bear the losses with-
out assistance from society.
D. Inadequacies of the Common Law Mechanisms
If we are willing to wait for its slow evolution, traditional com-
mon law concepts may provide, in the end, a patchwork of reme-
dies for experimental subjects who have not consented or who have
been injured under circumstances vitiating their consent. But even
if the common law does work when the issue is consent, it is un-
likely to develop a remedy for the injured subject who has freely
and validly consented to an experiment that is properly planned,
approved and executed. Assuming that the system of prospective
safeguards for human volunteers is operating well, the great major-
ity of experiments would be conducted correctly and would thus
leave the largest class of injured human subjects8 4 without a remedy.
83. Franklin, supra note 56, at 474-76. Franklin, in his article on liability
for hepatitis-infected blood transfusions, notes that some state legislatures have
chosen to condition the statutory elimination of strict liability for such trans-
fusions on the observance by hospitals of practices designed to screen out do-
nors likely to be hepatitis carriers. He proposes that in granting hospitals im-
munity from general tort liability legislatures require hospitals to carry first-
party insurance covering the medical expenses and lost income arising from
patients' transfusion-associated hepatitis, Id. at 477-79.
84. This assumes both the competence of the researchers to avoid negligent
mistakes and the efficacy of prospective reviews in eliminating unwarranted
procedures and assuring the efficacy of consent procedures.
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These people are the victims of disproven hypotheses. They drama-
tize the very risks that raise the moral dilemma in deciding whether
the use of human beings in experimentation is ever justified. And
yet, because the source of their injuries will be evident after the
fact, these subjects also epitomize the purpose behind experimen-
tation. The experiment having revealed the danger, large numbers
of individuals will be spared the type of injury the volunteers have
received.
The only common law concept that offers any possibility of giv-
ing these victims a remedy is absolute liability. At one time any
physician who injured his patient while using a nonstandard proce-
dure was held to a standard of absolute liability,85 but the courts re-
jected that reasoning long ago.86 Readopting strict liability ap-
pears to be inconsistent with society's decision to allow the use of
human volunteers because the probable result would be a severe re-
duction in the amount of medical research conducted. This reduc-
tion would defeat society's desire to advance medical knowledge as
rapidly as is consistent with responsible research techniques. How-
ever, were this contradiction resolved, the question would remain
whether absolute liability is a viable answer to the needs of the in-
jured subject. There is no doubt that the rapid advance of the-
ories of enterprise liability has eroded the traditionally strong as-
sociation of fault with liability apparently making strict liability a
good solution for the victims of faultless experiments. The difficulty
for the experimental context is that the courts have adopted enter-
prise liability only where there was a defective marketable product
or service, underscoring the fact that the motivation for moving
away from fault is primarily the search for deterrence and cost-
spreading mechanisms.
The application of enterprise liability to a properly conducted
medical experiment that results in -the unavoidable injury of a hu-
man volunteer breaks down in two respects. First, since by hypoth-
esis neither planning nor execution was defective, there is nothing
85. See, e.g., Carpenter v. Blake, 60 Barb. 488 (N.Y. Sup. Ct. 1871), rev'd
on other grounds, 50 N.Y. 696 (1872); Slater v. Baker, 95 Eng. Rep. 860 (K.B.
1767).
86. See, e.g., Fortner v. Koch, 272 Mich. 273, 282, 261 N.W. 762, 765
(1935), where the court said:
[l]f the general practice of medicine and surgery is to progress, there
must be experimentation carried on; but such experiments must be
done with the knowledge and consent of the patient or those responsi-
ble for him, and must not vary too radically from the accepted
method of procedure.
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short of not conducting the experiment that could have been done to
avoid the injury. Deterrence thus is not served by imposing abso-
lute liability. Secondly, as to cost-spreading, generally there is not a
currently marketable product that can serve as a device for passing
costs through to the public. For research focusing on experimental
procedures as opposed to experimental devices, even at the success-
ful conclusion of the experiment, there may not be an adequate
market structure capable of passing the costs to the beneficiaries of
the knowledge gained. Furthermore, even though proof that either
a procedure or a device is useless may represent an advance, the
failure of the research project means no market structure will mate-
rialize to impose costs on those who benefit from the knowledge
gained.
Beyond the theoretical difficulties with the use of absolute li-
ability in the experimental field, the practicalities of who is to bear
the costs of faultless liability are equally troubling. The individual
researchers or their supporting institutions might handle the costs
through insurance, but the high risk and the relatively small pool
through which to spread this cost suggest that insurance may not be
the most efficient cost-spreading device. If the institutions were un-
able to obtain insurance, they would be forced to become self-in-
surers. Institutions spread costs among -those who happen to be
patients and these would not necessarily be the beneficiaries of the
experimentation. The result is a most inequitable means of cost-
spreading. There is no objection to a cost-spreading scheme that
imposes costs throughout society since society in the aggregate is
benefitted by experimentation, originally mandated the research,
and has the capacity to regulate the research if the costs grow too
large. But it is manifestly unfair to burden only a segment of so-
ciety that is not directly aided and that is so burdened only through
the happenstance of being present at an institution where research
has produced an injury.
The imposition of liability through the common law carries a
stigma of condemnation that would be unacceptable from the stand-
point of the researcher. It cannot be expected that the imposition
of strict liability will be understood as only an attempt to help in-
jured subjects. The idea of liability without fault that is embod-
ied in enterprise liability is a new concept and to most people com-
mon law liability is still inextricably bound to some indication of
fault. Researchers and institutions who have conducted proper ex-
periments and met their duties to the subjects could understandably
interpret their liability as a condemnation of their humanitarian ef-
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forts. In the commercial setting, where enterprise liability was de-
veloped, the imposition of absolute liability is merely another ex-
pense which is crucial only if it destroys the profit-margin. In med-
ical experimentation, the reward system is more complicated and
more sensitive to the imposition of absolute liability. Having lia-
bility substituted for the praise of his or her efforts that the re-
searcher may have expected from society when he or she decided
to devote his or her talents to research could result in a decision to
forgo research for other readily available and more profitable al-
ternatives. There is a compelling argument, therefore, for legisla-
tive intervention in the field of experimental medicine, in order to
create a flexible system of compensation that would ensure justice
to the individual without discouraging the advancement of medical
knowledge.
IV. A PROPOSAL: FEDERAL COMPENSATION FUND
A. Coverage
Reliance on the common law with its attendant disfunctions may
work an injustice by leaving the victims of experimentation without
compensation. While the volunteer has not been wronged in the
traditional sense, he or she has been injured in an activity designed
to benefit society. To satisfy our sense of justice, society should
devise a system that places the costs on those who benefit. In
many ways, the situation resembles the one addressed by workmen's
compensation funds.
A comparison of the employment relation with medical experi-
mentation reveals several significant similarities. In both cases, ac-
tivities -that society deems necessary give rise to a certain number of
unavoidable injuries. Although statistical projections may predict
the total number of incidents, prospective identification of the par-
ticular activities that will result in injury is impossible. Therefore,
to avoid these injuries, society would have to forgo all hazardous ac-
tivities. Developing technology is a contributing factor to injury in
both industry and medical experimentation. The industrial revolu-
tion, by introducing complicated machinery, increased not only the
number of dangers in any given work situation but also possibly the
severity of the injury.87 Medical experimentation -finds its major
87. In the initial enthusiasm for progress that was generated by the indus-
trial revolution, the sketchy common law principle of employer liability for in-
juries received by his employees in the course of their duties was eroded. In-
sulating doctrines, such as the fellow-servant rule, were announced. Farwell
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justification for subjecting human beings to risk in the prospect of
improved medical technology. In both fields, use of common law
remedies to compensate the victims of the unavoidable injuries
growing out of greater sophistication has serious drawbacks. Prior
to the introduction of workmen's compensation, common law reme-
dies were available to some victims of work-related accidents, but
the requirement of a finding that the employer was solely responsi-
ble for the injury barred most injured workmen from common law
recovery. 88 Similarly, under present common law theories appli-
cable to experimental injuries, the requirement that some defect in
the execution be found to trigger liability appears to bar the major-
i ty of injured human volunteers from obtaining relief. This analysis
suggests that the workmen's compensation system may provide a
model for handling the compensation of injured human volunteers. 89
Before proceeding, however, the differences between the two
fields that may affect the model-building must be outlined. Work-
men's compensation had to face the difficult fact that workers who
were themselves at fault would be compensated for their injuries in
a significant percentage of cases.90 A balance was struck whereby
v. Boston & W.R.R., 45 Mass. (4 Met.) 49 (1849); Priestley v. Fowler,
150 Eng. Rep. 1030 (Ex. 1837). This development parallels the judicial rejec-
tion of the absolute liability of a physician who injures a patient in the course
of experimentation. See note 86 supra and accompanying text. However, as
the spread of industrialization gave rise to an ever-increasing number of indus-
trial accidents, courts began to move again toward doctrines supporting find-
ings of employer liability by creating exceptions to their initially broad insulat-
ing rules. See, e.g., Fitzwater v. Warren, 206 N.Y. 355, 99 N.E. 1042, 42
L.R.A. (n.s.) 1229 (1912) (employee does not assume the risk of employer's
violation of safety statute); Flike v. Boston & A.R.R., 53 N.Y. 549, 13 Am.
R. 545 (1873) (fellow-servant rule does not apply to employees responsible
for carrying out employer's common law duty to provide for employee safety);
Louisville, N. & Gr. S.R.R. v. Fleming, 82 Tenn. 128 (1884) (employee's con-
tributory negligence is only considered as mitigating damages). See generally
A. LARsON, THE LAW OF WORKMEN'S COMPENSATION §§ 4.10-.40 (1972).
88. In a study of industrial accidents in Germany in 1907, only 17 per-
cent of the reported injuries were attributed solely to the employer's fault.
This study also reported that 42 percent of all known industrial accidents in
one year in Germany were "inevitable accidents connected with employment."
A. LARSON, supra note 87, at § 4.30.
89. This assumes that with the present prospective reviews, few, if any,
unwarranted experiments will be performed. It further assumes the general
competence of researchers, discounting negligence as a major cause of injury.
These assumptions are difficult to test, however, because of the present lack
of data on the use of human subjects in the United States.
90. The 1907 German study indicated that in 29 percent of the reported
accidents, the injured employee was either negligent or at fault and in 5 per-
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work-related injuries were compensated regardless of fault, but both
the type of injury covered and the measure of damages were nar-
rowly drawn. In response to the view that the interest protected
was the worker's productive ability, for the most part only injuries
that impaired earning capacity were covered. The measure of dam-
ages being lost wages, all vestiges of recovery for pain and suffering
and for physical injuries not interfering with work functions were
eliminated. 91 Finally, since the worker's fault was ignored for pur-
poses of recovery, employers argued that their fault should similarly
be discounted. As a result, the legislatures have generally made
workmen's compensation the exclusive remedy available to the in-
jured employee, even in those cases where the injury was caused
solely by the employer's fault.
In the field of medical experimentation, fault is not the two-sided
coin that it is in industrial accidents. Injuries will rarely, if ever, re-
sult from the subject's negligence or fault. Therefore, the reasons
for limiting coverage in workmen's compensation to injuries affect-
ing the ability to work and for denying recovery for pain and suf-
fering are not operative in the esearcher-subject relationship. Fur-
thermore, since subject fault is not an issue, the researchers have no
basis for demanding that their fault also be ignored. In making
reference to the workmen's compensation model, we must not lose
sight of the policy and politics that caused it to preempt the control
system of the common law.
In any proposal for a compensation program for injured volun-
teers, the major questions are how it will treat fault and whether it
will stultify or even terminate the development of common law
remedies. The system proposed here is one that recognizes that the
injured volunteer's right to recover from a compensation fund should
both compensate and deter. The proposed fund is federal and
accomplishes broad but fair compensation through adoption of the
positional risk test, a workmen's compensation concept.92 An incen-
cent of the cases, the injured employee was jointly negligent with the employer.
A. LARsON, supra note 87, at § 4.30.
91. "A compensation system, unlike tort recovery, does not pretend to re-
store the claimant what he has lost; it gives him a sum which, added to his
remaining earnings ability, if any, will presumably enable him to exist without
being a burden to others." Id. § 2.50.
92. This term was first developed in the workmen's compensation field.
In the context of workmen's compensation, its application limits compensable
injuries to those which the employee would not have otherwise incurred had
he not been in the spatial position demanded by his work. This concept goes
beyond the traditional workmen's compensation standard of awarding compen-
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five to achieve adequate design control is created by not including
an exclusive remedy clause.
The proposed fund is federal in recognition of the degree to
which the federal government has legitimized the use of human vol-
unteers in medical experiments through its extensive direct funding
of research and indirect support of research institutions funded from
other sources. 93 Encouraging the advancement of medical knowl-
edge despite recognizable risks places responsibility on the federal
government to make provision for the proper allocation of the full
costs.
Although administered by the federal government, the fund
would not be limited to federally funded research. The benefits
that accrue to society when a particular hypothesis is proved or
disproved do not vary according to the nature of the project's fund-
ing. The results of medical experimentation, whether publicly or
privately funded, are published in journals that are widely distrib-
uted throughout the medical community. Depending on the stage
of the reported research, such dissemination encourages further ex-
perimentation, building on the hypothesis as altered by the results
of the reported experiment, or serves as .the basis for changing modes
of treatment. The nationwide activity stemming from the experi-
ment established the jurisdictional basis for federal intervention.94
sation only for injuries arising out of the employment by compensating for in-
juries inflicted by neutral risks. Id. §§ 10.00-.33.
We use the term positional risk to make it clear that the standard for com-
pensability in the context of medical experimentation is whether the injury
would have been avoided if the victim had not participated in the experiment.
93. The continued federal activity in this area is manifested in the Na-
tional Research Service Award Act of 1974, Pub. L. No. 93-348, 88 Stat. 342.
94. Cf. 7 U.S.C. §§ 2131-55 (1966), which creates federal procedures in-
cluding licensing for research facilities that use experimental animals trans-
ported in interstate commerce and for dealers and exhibitors of such animals.
One of the express congressional intentions in adopting this law in 1966 was
"to insure that certain animals intended for use in research facilities or for ex-
hibition purposes or for use as pets are provided humane care and treatment."
Id. § 2131.
Although the interstate commerce connection may seem attenuated since
the regulated activities may be initially limited in scope to one state, or the
primary interstate commerce resulting from the experiment may be only jour-
nal articles and other correspondence, other federal regulation grounded on the
interstate commerce clause has been found appropriate on arguably minimal
jurisdictional acts. United States v. Sullivan, 332 U.S. 689 (1948), upheld the
constitutionality of the Federal Food and Drug Act of 1938 in regulating the
treatment of drugs even after their interstate transport was complete. Mande-
ville Island Farms v. American Crystal Sugar Co., 334 U.S. 219 (1948), recog-
nized that if a product is ultimately to pass into interstate commerce, there
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We have seen that the federal government's encouragement of re-
search has made it the most appropriate administrator of the fund.
Its taxing structure is also the most efficient means of distributing
costs to society, which is the real beneficiary because the current
market structure is incapable of passing the costs of proving or dis-
proving an hypothesis on to society.
As an initial proposition, the possibility that the availability of
such compensation to injured volunteers would be interpreted as
license to embark on high-risk experiments cannot be discounted.95
To guard against such reactions, it is suggested that each research
project that puts human subjects at risk should be roughly catego-
rized according to the probability of the risk materializing and the
severity of the possible injury.96 If the combination of severity
and probability of risk is high by relative standards but within ac-
ceptable limits because of the importance of the expected findings,
the researcher and/or the, sponsoring institution should be asked to
indemnify the fund for a percentage of any damages that might oc-
is constitutional power for the Congress to create a private cause of action for
antitrust conduct that took place entirely intrastate, prior to the entry of the
product into interstate commerce. More recently, the Supreme Court upheld
the constitutionality of Title II of the 1964 Civil Rights Act and its application
to a small family-owned restaurant in Birmingham, Alabama, Ollie's Barbecue,
as valid exercises of federal power under the interstate commerce clause in
Katzenbach v. McClung, 379 U.S. 294 (1964). See Heart of Atlanta Motel
v. United States, 379 U.S. 241 (1964). In that Act, Congress exerted its
power over interstate commerce as a jurisdictional basis to control a social
problem, a use of that power similar to the proposal made here. Finally, while
the commerce clause powers are generally used in relation to tangible items,
the intangible commodity of insurance coverage has been held to be subject
to federal regulation under the commerce clause. United States v. South East-
era Underwriters Ass'n, 322 U.S. 533 (1944).
95. Having removed the employer's liability in tort, many workmen's com-
pensation systems have included various devices to create incentives for the em-
ployer to exercise care. Where employers obtain private insurance, the pros-
pect of increased premiums is such an incentive. In states with public funds,
linking the employer's rate of contribution to the fund to his individual experi-
ence rating is a similar incentive. In many instances, such devices alone have
not resulted in lowering accident rates to an acceptable level, as evidenced by
separate statutes that require specific safety measures. Whether continued em-
ployer liability in tort for injuries to workers arising out of employer fault
would have made such statutes unnecessary must be left largely to the realm
of speculation.
96. The existing prospective review of research proposals should prevent
most excessively risky experiments, but the compensation fund by reviewing
the risks to allocate relative liability provides another layer of deterrence,
thereby helping to protect the individual from unjustified human experimenta-
tion.
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cur. The extent of the indemnification would be commensurate
with the risk. Other considerations such as the identity of the sub-
jects-adults, children, institutionalized persons-or the likelihood
of benefit to the subjects would also be significant in working out
an indemnification agreement. For example, an experiment with a
relatively low possibility of risk, involving a minor potential injury,
among a group of adults for whom there is a high probability of
benefit would usually call for no indemnification by the researcher
or the sponsoring institution. On the other hand, an experiment
with a high risk of serious injury among the same group of subjects
might call for 30 percent indemnification. This high-risk experi-
ment conducted on a group of subjects with no expectation of any
direct benefit might involve 40 percent indemnification.
Whether the injury would have been avoided had the subject
not participated in the experiment should be -the sole criterion for
determining which injuries would be compensable. Such posi-
tional risk analysis would not necessarily result in compensation
for all -the injuries a subject might sustain during the course
of an experiment. Many subjects participate in experiments in
the hope that the experiment will produce a cure for the disease
from which they suffer. The criteria set out would limit coverage
to the injuries that would not have occurred or been likely to have
occurred had a normal therapeutic course been pursued. 97 The
significant fact to be emphasized is that under this plan the possi-
bility of therapeutic benefit from the experiment would not preclude
the subject from recovery altogether. At the other end of the spec-
trum, if the subject does not stand to benefit directly, all injuries
he or she experiences would be covered. Clearly the gradations
between these two situations are many and difficult to draw, but the
application of the single standard is most reflective of the true
costs, providing windfalls neither to the subject at the expense of
society nor to society at the expense of the subject.
Questions of fault would not be entertained in relation to the is-
sue of what is a compensable injury. However, unlike the typical
workmen's compensation program, fault could retain significance
in the medical experiment compensation fund. Once a claim was
found to be substantial, the possibility that fault was a causative
factor in the injury would be investigated. When the inquiry moved
from the question of compensability of the injury to the question of
fault, the burden of proof would shift to the researcher. The fea-
97. See note 92 supra and accompanying text.
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ture of placing the researcher in the position of -affirmatively show-
ing absence of fault would enhance the control aspects of the sys-
tem. When the investigation suggested that there was a basis for
common law fault liability, the victim would be free to pursue the
available common law remedies. If he or she were successful in
winning a judgment, he or she would reimburse the compensation
fund in the amount of the award. If the victim were not prepared
to pursue the potential common law remedies, even though the inves-
tigation suggests that fault was a factor, the compensation fund
would be empowered to seek common law relief to the extent of
the award actually made to the victim plus administrative and liti-
gation costs. In other words, the compensation fund would only
arrest development of the common law remedies not founded on
fault.
Creating a two-step system of an administrative proceeding fol-
lowed, when fault appears to be an issue, by a judicial proceeding
may seem cumbersome, but it appears to be the most appropriate
mechanism for maximizing the conflicting goals of victim compen-
sation and continued common law development. First, compensa-
tion is certain and prompt. Basic compensation to the victim is not
left to the vagaries of the common law of the jurisdiction or to the
happenstance of the particular events of the injury. The procedure
will serve the important goal of providing more expeditious payment
of compensation than is available from a civil suit. Secondly, be-
cause recourse to the common law is retained, researchers and
their supporting institutions are not insulated from the results of
their wrongful acts. All those involved in medical experimentation
using human volunteers will have a strong incentive to plan and exe-
cute their projects with the greatest care.
The complex compensation fund system finds further justifica-
tion in its ability to explore the currently undefined dimensions of
researcher fault. A compensation system having no stake in deter-
mining the fault issue would shed little light on this important
question.9s Experience with the system may well reveal that re-
98. The compensation system proposed in Note, Medical Experiment In-
surance, 70 COLUM. L. REv. 965 (1970), leaves two major tasks unaccom-
plished. In failing to address the question of fault, it creates no deterrent
mechanisms. In focusing on compensation of experimentation victims to the
exclusion of other goals, it would provide only half of the information needed
to determine the degree to which deterrence should be a concern. In addition,
that proposal would give us a numerator but no denominator for computing
the ratio of injured subjects to the total number of human subjects used
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searcher fault has been reduced to an insignificant problem
through successful prospective controls and the minimization of error
by researchers sensitive to their responsibilities in using human sub-
jects.
If it becomes apparent that researcher fault is a minimal prob-
lem, presently available sanctions, other than recourse to judicial
common law remedies, would be sufficient. It is already contem-
plated by the present regulations issued by the Department of
Health, Education, and Welfare that a finding of failure to dis-
charge either personal or institutional responsibilities for the protec-
tion of the rights and welfare of human subjects should be a major
factor in considering applicants for future funding.99 A finding of
fault would also be possible grounds for termination or suspension
of present funding.' 00
Just as the federally administered fund would not interfere
with development of most common law remedies in the forum of
the state courts, neither would the federally imposed standards dis-
place the authority of the individual states to discipline their prac-
titioners. In fact, cooperation between the federal system and the
state medical boards should be maximized. It is to be anticipated
that the multifaceted controls would draw the criticism that new
and unusual burdens were being placed on the practitioner. In re-
sponse, it should be emphasized that the system would apply only
to human experimentation, an unusual and hazardous activity that
the federal government supports directly and indirectly. Under
these circumstances, the federal government is justified in playing an
extensive reinforcing role in administering controls.
Gathering information on the general scope of medical experi-
mentation is essential in pinpointing the specific problem areas.
Prior to starting the experiment, an informational statement would
be required of all human experimentation projects. In cases where
in experimentation in the United States. It would also fail to provide data
for a qualitative analysis of these figures.
99. See 45 C.F.R. § 46.21 (1974), which provides for early termination
of awards and prejudice in being considered for subsequent grants where a re-
searcher or institution has failed to comply with the federal regulations gov-
erning the use of human volunteers.
100. The major shortcoming of the present provision for considering prior
failure to observe the federal standards for using human volunteers is that it
is limited to scrutiny only of prior experiments that were themselves subject
to federal regulation. See 45 C.F.R. § 46.21 (1974). The system here pro-
posed would for the first time allow the gathering of data on all research that
places human subjects at risk and place in perspective the resulting injuries.
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the experimental proposal is reviewed by the supporting institution,
copies of documents prepared for that purpose likely will be suffi-
cient. For research conducted in settings where such review is not
required, this report will impose an added requirement on the re-
searcher, but a minimal one. The report would consist of notifica-
tion of the intent to use human subjects, an outline of the intended
conduct of the experiment, an estimate of how many subjects were
to be used, and a statement of the review procedures to which the
proposal had been submitted. On the basis of this Teport, the level of
indemnification, if any, from the researcher and/or the supporting
institution would be determined. At the close of the experiment, a
similarly brief notification would be filed with the fund indicating
the actual number of -human subjects and the occurrence of any in-
juries. The filing of this final report should not be confused with a
statute of limitations against subjects whose injury from the experi-
ment becomes apparent only after a long passage of time. Any in-
jury which can be shown to result from medical experimentation
should be compensated, regardless of when it becomes manifest.
Any statute of limitations should run only from that time. It must
be stressed that these reports are information-gathering devices.
They would not be designed to be the basis for a wholesale review
of the proposed project but would encourage the growth of review
procedures at the research institution, where they would be most
effective. 10 They would serve as the basis of the indemnification
determination and give the first overall picture of the state of human
experimentation in the United States. The information assembled
from these reports should place society in a position to evaluate the
true costs of -its commitment to the rapid advance of medical knowl-
edge more closely. Informed decisions as to the viability of con-
tinuing 'that commitment will then become possible.
One of the most difficult problems in creating the compensa-
tion fund is measuring the "cost" of the injury to the human sub-
jects. The compensation fund would naturally cover the direct and
readily ascertainable cost of medical expenses and loss of earnings,
but should the coverage extend to the cost of pain and suffering?
Unless both the compensation and control features of the program
are to become illusory for that significant portion of human subjects
who are already ill, aggravated pain and suffering must be a basis
for compensation. The healthy subject and the unhealthy one
101. See generally note 13 supra; Cowan, Human Experimentation: The
Review Procedure in Practice, 25 CASE W. RES. L. REv. 533 (1975).
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would be entitled to compensation for the pain and suffering re-
sulting from the untoward consequences of their participation in the
study. The measure of this kind of award could be calculated as it
is in traditional tort law. However, the award would not cover the
pain and suffering that is an anticipated result of the experiment
and of which the subject was apprised. In that case the subject
would have consented to the pain and suffering and may have been
compensated for itas a condition to agreeing to participate.
B. Mechanics
The mechanics of the system proposed here would be simple.
When a researcher determined that an experiment would place hu-
man beings at risk,102 he or she would file a form with the compensa-
tion fund stating the nature of the experiment, the probability of
injury, the severity of the injury if it should occur, and the number
of subjects. 103 In most cases the report to the fund would be re-
viewed at the same time by the researcher's sponsoring institution in
considering whether the use of human subjects in the proposed
study is justified and if so whether procedures for obtaining con-
sent are adequate. The sponsoring institution would also have an
obligation to review the initial report made to the fund to ensure
that it was as accurate a reflection of the characteristics of the ex-
periment as could be prepared prospectively. The initial report
would provide the fund with the needed information on risk to de-
cide if partial indemnification were required and if so at what level.
If the fund decided a percentage indemnification were necessary,
assuming the researcher and the sponsoring institution were willing
to accept the liability, an agreement would be signed.10 4
In the event that the experiment were performed without injury,
which can reasonably be expected in the vast majority of cases,
the only other form that would need to be filed with the compensa-
102. Cf. 45 C.F.R. § 46.11 (1974).
103. Such a report would resemble an abbreviated environmental impact
statement in its intended use.
104. If the researcher and/or his sponsoring institution were to dispute a
compensation board's initial assessment of risk, provision could be made for
a de novo hearing on the appropriate percentage of indemnification, should an
injury actually occur. To avoid this becoming an issue with every injury, how-
ever, the parties responsible for indemnification should be required to reserve
specifically their right to challenge the initial determination of risk in the
event injury occurs. The time of the researchers and the resources of the com-
pensation system should not be expended in disputes over this issue unless in-
demnification is actually required, when a compensable injury has occurred.
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tion fund would be a closing statement verifying the actual number
of subjects used in the course of the study and that no immediate in-
jury had occurred to any of them as a result of their participation.
These reports would provide needed data for a perspective on how
human subjects are being used in the United States and at what risk.
If an injury did occur during the experiment, a claim would
immediately be filed with the fund. Accompanying the claim
would be a full explanation of the circumstances of the injury, indi-
cating whether it fell within the range of risk initially reported to
the fund. If the injury were not the result of negligence and if
there were no other irregularity in the experiment (e.g., failure to
obtain adequate consent), the fund would pay the claim and seek
any indemnification agreed upon under the initial agreement with
the researcher and his sponsoring institution. This would constitute
a final settlement of the claim.
If the evidence suggested researcher negligence or other irregu-
larity, the fund would still pay the claim, but this would be only the
first step. The payment of the claim would leave the subject free
to pursue the common law remedies available in the jurisdiction
where the experiment took place. If a person received compensa-
tion from the fund and subsequently recovered under common law,
the fund would be reimbursed from the judgment. Alternatively,
the failure of the subject or his representative to seek common law
redress would give the fund the right to sue the party at fault in
court for the amount paid to the claimant plus -the fund's costs of
administration and litigation. Any judgment the fund received in
excess of the award originally made would be given to the claim-
ant.
V. CONCLUSION
The common law, by acting after the fact to assess the relative
rights and liabilities of parties involved in an experiment that has
produced an injury, accords two advantages. First, retrospective
examination of the cases avoids delay of experimentation. Secondly,
consideration of only those cases where -there is reason to think an
injury or other wrong has occurred results in the most efficient ex-
penditure of time and attention. Given the lifesaving intent of the
activities to be regulated by the system proposed here, objections
of delay and inefficiency cannot be lightly dismissed. However, the
concern over delay is illusory, because this system will not be oper-
ating in a vacuum. Its prospective devices provide neither the
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first nor the only scrutiny to which most experiments will be sub-
jected. The present regulations governing review of projects di-
rectly funded by the government and those conducted in institutions
receiving substantial government support are an existing check
against the premature launching of experimental programs. The
goal of the compensation fund proposal would be to execute its
prospective procedures during the same period as the presently re-
quired review. Achieving coordination of the new procedures with
the existing ones would make objections of delay unwarranted,
since the choice to impose preexperiment review has already been
made.
Furthermore, to the extent that the proposed system will operate
with information already required by present review procedures, it
cannot be seen as a seriously inefficient expenditure of resources.
Rather, the contemplated procedures improve efficiency by making
double use of the information generated prior to -the experiment.
-More significantly, essential notions of fairness and equity argue
against giving credence to criticism based on minimal delays or in-
efficiencies. The inability of the common law to provide redress
in the majority of injury cases-where the injuries were not the re-
sult of researcher fault-underscores -the need to create a sure rem-
edy for these victims. A compensation fund supported out of the
federal tax structure would achieve the proper nexus between cost
and benefit. At the same time, the indemnification agreements
would inject the requisite measure of deterrence into the scheme.
Finally, the proposed system would ensure just compensation of vic-
tims without placing the largely unjustified stigma of fault on the re-
searcher.
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